内脏脂肪素与冠心病
|
摘要
第一部分内脏脂肪素对脐静脉内皮细胞合成单核细胞趋化蛋白-1和白介素-6影响的研究
目的和背景:内脏脂肪素(Visfatin)是一种新的脂肪因子参与调节炎症因子合成和分泌。单核细胞趋化蛋白-1(MCP-1)和白介素-6(IL-6)参与动脉粥样硬化的重要炎症因子之一,本研究探讨内脏脂肪素是否能调节内皮细胞MCP-1和IL-6生成以及信号转导机制。
方法:培养3-5代脐静脉内皮细胞(HUVEC),给予不同剂量和不同干预时间的内脏脂肪素刺激HUVEC。内脏脂肪素刺激基础上给予不同蛋白激酶抑制剂:渥曼青霉素(磷酸肌醇3激酶(PI3K)抑制剂)、SB203580(p38丝裂原活化蛋白激酶(MAPK)抑制剂)、PD98059(细胞外信号调节激酶(ERK)抑制剂)、JNK inhibitorⅡ(c-Jun氨基末端激酶(JNK)抑制剂)和HNMPA-(AM)3(胰岛素受体酪氨酸激酶抑制剂),ELISA测定培养液MCP-1和IL-6浓度,实时定量聚合酶链反应(RT-PCR)测定细胞MCP-1和IL-6 mRNA表达。
结果:内脏脂肪素刺激HUVEC合成MCP-1和IL-6,呈剂量和时间依赖性,内脏脂肪素浓度为500ng/mL或作用时间48小时后MCP-1和IL-6表达达到高峰;渥曼青霉素、SB203580、PD98059等蛋白激酶抑制剂能阻断内脏脂肪素诱导的MCP-1、IL-6合成,并抑制MCP-1、IL-6 mRNA表达。胰岛素受体抑制剂HNMPA-(AM)3预处理HUVEC,阻断内脏脂肪素诱导的MCP和IL-6蛋白和基因表达。
结论:本研究表明内脏脂肪素能诱导HUVEC合成MCP-1和IL-6,其可能的信号转导通路包括p38 MAPK,P13K、ERK 1/2以及胰岛素受体旁路。
第二部分内脏脂肪素与炎症、动脉粥样硬化和急性冠脉综合征
目的和背景内脏脂肪素(Visfatin)为最近新发现的脂肪因子,能结合胰岛素受体模拟胰岛素发挥作用,可能与肥胖和胰岛素抵抗有关。最近文献表明内脏脂肪素与炎症、内皮功能失调、动脉粥样斑块不稳定性相关。然而内脏脂肪素在动脉粥样硬化的病理生理机制中具体作用还未明确,因此该研究目的为评价血浆内脏脂肪素与炎症、动脉粥样硬化以及急性冠脉综合征(ACS)之间的联系。
方法253例临床怀疑冠心病的患者均行冠状动脉造影,分为三组:稳定性心绞痛(SAP)(102例)、ACS(100例)和无冠心病对照组(51例)。测定循环血中内脏脂肪素、单核细胞趋化蛋白-1(MCP-1)、白介素-6(IL-6)、高敏C反应蛋白(hs-CRP)等细胞因子,探讨内脏脂肪素和传统危险因素、炎症、动脉粥样硬化以及急性冠脉综合征之间的联系。
结果SAP和ACS患者血浆内脏脂肪素水平较无冠心病对照组患者明显升高(分别为12.0(9.7,15.5)12.0 ng/mL,13.4(11.1,15.9)ng/mL,10.2(8.7,12.8)ng/mL,p＜0.05)。亚组分析表明冠心病患者是否合并糖尿病、高脂血症、肥胖症血浆内脏脂肪素水平无显著性差异。多元线性回归分析表明内脏脂肪素与IL-6、MCP-1、空腹血糖(FPG)正相关,β值分别为0.0029、0.337和0.104。多因素logistic回归分析调整传统危险因素和炎症性因素后显示血浆内脏脂肪素水平与SAP和ACS密切相关。血浆内脏脂肪素水平位于第2、3、4四分位数区间的人群SAP危险比数比(OR)分别为1.74(0.96,2.69)、1.54(0.85,2.28)和1.84(0.98,2.87),ACS分别为2.56(1.57,3.34)、4.61(1.94,10.96)和6.52(2.34,18.12)。
结论血浆内脏脂肪素水平与冠心病相关,尤其是与ACS相关,独立于其它传统危险因素。
Part One Effects of visfatin on production of monocyte mhemotactic protein-1 and interleukin-6 in Human Vein Umbilical Endothelial Cells
Objective and Backgroud:Visfatin is a novel adipocytokine affecting insulin resistance by binding to the insulin receptor and considered a new proinflammatory adipocytokine. Monocyte chemotactic protein-1(MCP-1) and interleukin-6(IL-6) are importantly inflammatory cytokines involved in atherosclerosis.Whether visfatin stimulates MCP-1 and IL-6 production in human endothelial cells and what signaling pathways are involved in are not known.
Methods:Cultured human umbilical vein endothelial cells(HUVEC) were treated with different doses and durations of visfatin.Furthermore,HUVEC were pretreated with wortmannin,a phosphatidylinositol-3-kinase(PI3K) inhibitors,PD98059,an extracellular regulated kinase kinase(ERK) inhibitor,SB203580,a mitogen-activated protein kinase(p38 MAPK) inhibitors and hydroxy-2-naphthalenylmethylphosphonic acid trisacetoxymethyl ester(HNMPA-(AM)3),a specific inhibitor of insulin receptor (IR) followed by visfatin(100ng/mL) treatment.Enzyme-linked immunosorbent assay (ELISA) was used for measuring MCP-1 and IL-6 production in HUVEC.Real-time quantitative reverse-transcription polymerase chain reaction(Real-time-PCR) was used for determining MCP-1 and IL-6 mRNA expression.
Results:In the present study,we demonstrated that visfatin significantly and dose-and time-dependently up-regulated protein production of MCP-1 and IL-6 in HUVEC,which the dose of 500ng/mL or 48 hours duration of visfatin treatment had the maximal effect. We therefore found visfatin-induced MCP-1 and IL-6 production and gene expression in HUVEC were diminished by wortmannin,PD98059 and SB203580.Furthermore, HNMPA-(AM)3 also reduced visfatin-mediated MCP-1 and IL-6 production and gene expression in HUVEC.
Conclusions:Our findings suggest that visfatin might induce endothelial MCP-1 and IL-6 production in HUVEC with dose- and time-dependently manner.This dysregulation appears to be mediated in part via p38,PI3K and ERK signaling pathways,as well as insulin receptor pathway.
Part Two Association between Plasma Visfatin Levels and Inflammation, Atherosclerosis,and Acute Coronary Syndromes in Humans
Objective and Backgroud:Visfatin is a new cytokine that act as an insulin analog on the insulin receptor and may link to obesity and insulin resistance.It was recently shown visfatin play a role in inflammation,dysfunction of endothelium and plaque destabilization.However,the role of visfatin in atherosclerosis remains to be elucidated. We sought to assess whether plasma visfatin level can be independently associated with inflammation,atherosclerosis,and acute coronary syndromes(ACS).
Mathods:Two hundred fifty-three patients undergoing coronary angiography were divided into three subgroups:stable angina pectoris(SAP)(n=102),ACS(n=100) and the control patients(n=51).Clinical and biochemical characteristics were collected.The plasma samples were thawed and analyzed for circulating visfatin,monocyte chemoattractant protein 1(MCP-1),interleukin-6(IL-6) by enzyme-linked immunosorbent assay(ELISA).The levels of high-sensitivity C-reactive protein(hs-CRP) were determined by immunoturbidometry,The association of visfatin with risk factors, inflammation and atherosclerosis,as well as ACS were determined.
Results:Plasma visfatin levels were significantly higher in SAP(12.0(9.7,15.5)pg/mL, p＜0.05) and ACS(13.4(11.1,15.9) pg/mL,p＜0.01)compared with control patients (10.2(8.7,12.8) pg/mL).Subgroup analysis in all patients with coronary artery disease confirmed that plasma visfatin level were not significantly difference in with or without diabetes,with or without hyperlidimia,with or without obesity.Multiple regression analysis demonstrated that plasma visfatin levels positively correlated with MCP-1,IL-6 and FPG(βvalue for MCP-1,IL-6,FPG were 0.0029,0.337,0.104,respectively). Logsitic regression analysis demonstrated that plasma visfatin levels were associated with SAP(odds ratio[OR][95%confidence interval],for in the second,third and fourth quartiles were 1.74[0.96 to 2.69],1.54[0.85 to 2.28]and 1.84[0.98 to 2.87], respectively),ACS(ORs for in the second,third and fourth quartiles were 2.56[1.57 to 3.34],4.61[1.94 to 10.96]and 6.52[2.34 to 18.12],respectively)following adjustment for established risk factors and other inflammatory factors.
Conclusions:Plasma visfatin levels are significantly associated with CAD,particularly ACS,independent of well-known CAD risk factors.
目的和背景:内脏脂肪素(Visfatin)是一种新的脂肪因子参与调节炎症因子合成和分泌。单核细胞趋化蛋白-1(MCP-1)和白介素-6(IL-6)参与动脉粥样硬化的重要炎症因子之一,本研究探讨内脏脂肪素是否能调节内皮细胞MCP-1和IL-6生成以及信号转导机制。
方法:培养3-5代脐静脉内皮细胞(HUVEC),给予不同剂量和不同干预时间的内脏脂肪素刺激HUVEC。内脏脂肪素刺激基础上给予不同蛋白激酶抑制剂:渥曼青霉素(磷酸肌醇3激酶(PI3K)抑制剂)、SB203580(p38丝裂原活化蛋白激酶(MAPK)抑制剂)、PD98059(细胞外信号调节激酶(ERK)抑制剂)、JNK inhibitorⅡ(c-Jun氨基末端激酶(JNK)抑制剂)和HNMPA-(AM)3(胰岛素受体酪氨酸激酶抑制剂),ELISA测定培养液MCP-1和IL-6浓度,实时定量聚合酶链反应(RT-PCR)测定细胞MCP-1和IL-6 mRNA表达。
结果:内脏脂肪素刺激HUVEC合成MCP-1和IL-6,呈剂量和时间依赖性,内脏脂肪素浓度为500ng/mL或作用时间48小时后MCP-1和IL-6表达达到高峰;渥曼青霉素、SB203580、PD98059等蛋白激酶抑制剂能阻断内脏脂肪素诱导的MCP-1、IL-6合成,并抑制MCP-1、IL-6 mRNA表达。胰岛素受体抑制剂HNMPA-(AM)3预处理HUVEC,阻断内脏脂肪素诱导的MCP和IL-6蛋白和基因表达。
结论:本研究表明内脏脂肪素能诱导HUVEC合成MCP-1和IL-6,其可能的信号转导通路包括p38 MAPK,P13K、ERK 1/2以及胰岛素受体旁路。
第二部分内脏脂肪素与炎症、动脉粥样硬化和急性冠脉综合征
目的和背景内脏脂肪素(Visfatin)为最近新发现的脂肪因子,能结合胰岛素受体模拟胰岛素发挥作用,可能与肥胖和胰岛素抵抗有关。最近文献表明内脏脂肪素与炎症、内皮功能失调、动脉粥样斑块不稳定性相关。然而内脏脂肪素在动脉粥样硬化的病理生理机制中具体作用还未明确,因此该研究目的为评价血浆内脏脂肪素与炎症、动脉粥样硬化以及急性冠脉综合征(ACS)之间的联系。
方法253例临床怀疑冠心病的患者均行冠状动脉造影,分为三组:稳定性心绞痛(SAP)(102例)、ACS(100例)和无冠心病对照组(51例)。测定循环血中内脏脂肪素、单核细胞趋化蛋白-1(MCP-1)、白介素-6(IL-6)、高敏C反应蛋白(hs-CRP)等细胞因子,探讨内脏脂肪素和传统危险因素、炎症、动脉粥样硬化以及急性冠脉综合征之间的联系。
结果SAP和ACS患者血浆内脏脂肪素水平较无冠心病对照组患者明显升高(分别为12.0(9.7,15.5)12.0 ng/mL,13.4(11.1,15.9)ng/mL,10.2(8.7,12.8)ng/mL,p＜0.05)。亚组分析表明冠心病患者是否合并糖尿病、高脂血症、肥胖症血浆内脏脂肪素水平无显著性差异。多元线性回归分析表明内脏脂肪素与IL-6、MCP-1、空腹血糖(FPG)正相关,β值分别为0.0029、0.337和0.104。多因素logistic回归分析调整传统危险因素和炎症性因素后显示血浆内脏脂肪素水平与SAP和ACS密切相关。血浆内脏脂肪素水平位于第2、3、4四分位数区间的人群SAP危险比数比(OR)分别为1.74(0.96,2.69)、1.54(0.85,2.28)和1.84(0.98,2.87),ACS分别为2.56(1.57,3.34)、4.61(1.94,10.96)和6.52(2.34,18.12)。
结论血浆内脏脂肪素水平与冠心病相关,尤其是与ACS相关,独立于其它传统危险因素。
Part One Effects of visfatin on production of monocyte mhemotactic protein-1 and interleukin-6 in Human Vein Umbilical Endothelial Cells
Objective and Backgroud:Visfatin is a novel adipocytokine affecting insulin resistance by binding to the insulin receptor and considered a new proinflammatory adipocytokine. Monocyte chemotactic protein-1(MCP-1) and interleukin-6(IL-6) are importantly inflammatory cytokines involved in atherosclerosis.Whether visfatin stimulates MCP-1 and IL-6 production in human endothelial cells and what signaling pathways are involved in are not known.
Methods:Cultured human umbilical vein endothelial cells(HUVEC) were treated with different doses and durations of visfatin.Furthermore,HUVEC were pretreated with wortmannin,a phosphatidylinositol-3-kinase(PI3K) inhibitors,PD98059,an extracellular regulated kinase kinase(ERK) inhibitor,SB203580,a mitogen-activated protein kinase(p38 MAPK) inhibitors and hydroxy-2-naphthalenylmethylphosphonic acid trisacetoxymethyl ester(HNMPA-(AM)3),a specific inhibitor of insulin receptor (IR) followed by visfatin(100ng/mL) treatment.Enzyme-linked immunosorbent assay (ELISA) was used for measuring MCP-1 and IL-6 production in HUVEC.Real-time quantitative reverse-transcription polymerase chain reaction(Real-time-PCR) was used for determining MCP-1 and IL-6 mRNA expression.
Results:In the present study,we demonstrated that visfatin significantly and dose-and time-dependently up-regulated protein production of MCP-1 and IL-6 in HUVEC,which the dose of 500ng/mL or 48 hours duration of visfatin treatment had the maximal effect. We therefore found visfatin-induced MCP-1 and IL-6 production and gene expression in HUVEC were diminished by wortmannin,PD98059 and SB203580.Furthermore, HNMPA-(AM)3 also reduced visfatin-mediated MCP-1 and IL-6 production and gene expression in HUVEC.
Conclusions:Our findings suggest that visfatin might induce endothelial MCP-1 and IL-6 production in HUVEC with dose- and time-dependently manner.This dysregulation appears to be mediated in part via p38,PI3K and ERK signaling pathways,as well as insulin receptor pathway.
Part Two Association between Plasma Visfatin Levels and Inflammation, Atherosclerosis,and Acute Coronary Syndromes in Humans
Objective and Backgroud:Visfatin is a new cytokine that act as an insulin analog on the insulin receptor and may link to obesity and insulin resistance.It was recently shown visfatin play a role in inflammation,dysfunction of endothelium and plaque destabilization.However,the role of visfatin in atherosclerosis remains to be elucidated. We sought to assess whether plasma visfatin level can be independently associated with inflammation,atherosclerosis,and acute coronary syndromes(ACS).
Mathods:Two hundred fifty-three patients undergoing coronary angiography were divided into three subgroups:stable angina pectoris(SAP)(n=102),ACS(n=100) and the control patients(n=51).Clinical and biochemical characteristics were collected.The plasma samples were thawed and analyzed for circulating visfatin,monocyte chemoattractant protein 1(MCP-1),interleukin-6(IL-6) by enzyme-linked immunosorbent assay(ELISA).The levels of high-sensitivity C-reactive protein(hs-CRP) were determined by immunoturbidometry,The association of visfatin with risk factors, inflammation and atherosclerosis,as well as ACS were determined.
Results:Plasma visfatin levels were significantly higher in SAP(12.0(9.7,15.5)pg/mL, p＜0.05) and ACS(13.4(11.1,15.9) pg/mL,p＜0.01)compared with control patients (10.2(8.7,12.8) pg/mL).Subgroup analysis in all patients with coronary artery disease confirmed that plasma visfatin level were not significantly difference in with or without diabetes,with or without hyperlidimia,with or without obesity.Multiple regression analysis demonstrated that plasma visfatin levels positively correlated with MCP-1,IL-6 and FPG(βvalue for MCP-1,IL-6,FPG were 0.0029,0.337,0.104,respectively). Logsitic regression analysis demonstrated that plasma visfatin levels were associated with SAP(odds ratio[OR][95%confidence interval],for in the second,third and fourth quartiles were 1.74[0.96 to 2.69],1.54[0.85 to 2.28]and 1.84[0.98 to 2.87], respectively),ACS(ORs for in the second,third and fourth quartiles were 2.56[1.57 to 3.34],4.61[1.94 to 10.96]and 6.52[2.34 to 18.12],respectively)following adjustment for established risk factors and other inflammatory factors.
Conclusions:Plasma visfatin levels are significantly associated with CAD,particularly ACS,independent of well-known CAD risk factors.
引文
1 Ueda A,Okuda K,Ohno S,et al.NF-k B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene.J Immunol.1994,153:2052-2063.
2 Braunersreuther V,Mach F,Steffens S.The specific role of chemokines in atherosclerosis.Thromb Haemost.2007,97:714-21.
3 Naka T,Nishimoto N,Kishimoto T.The paradigm of IL-6:from basic science to medicine.Arthritis Res.2002,3:S233-S242.
4 Lotz M:Interleukin-6.Cancer Invest.1993,11:732-742.
5 Yudkin JS,Kumari M,Humphries SE,Mohamed-Ali V.Inflammation,obesity,stress and coronary heart disease:is interleukin-6 the link? Atherosclerosis.2002.148:209-14.
6 Eckel RH,York DA,R(o|¨)ssner S,et al.American Heart Association.Prevention conference Ⅶ:obesity,a worldwide epidemic related to heart disease and stroke:executive summary.Circulation.2004,110:2968-2975.
7 Skurk T,Alberti-Huber C,Herder C,Hauner H.Relationship between adipocyte size and adipokine expression and secretion.J Clin Endocrinol Metab.2007,92:1023-1033.
8 Yudkin,J.S.Inflammation,obesity,and the metabolic syndrome.Horm Metab Res.2007,39:707-9.
9 Hotamisligil GS,Shargill NS,Spiegelman BM.Adipose expression of tumor necrosis factor-α:direct role in obesity- linked insulin resistance.Science.1993,259:87-91.
10 Fain JN,Madan AK,Hiler ML,et al.Comparison of the release of adipokines by adipose tissue,adipose tissue matrix,and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans.Endocrinology.2004,145:2273-2282.
11 Shimomura I,Funahashi T,Takahashi M,et al.Enhanced expression of PAI-1 in visceral fat:possible contributor to vascular disease in obesity.Nat Med.1996,2:800-803.
12 Friedman JM,Halaas JL.Leptin and the regulation of body weight in mammals.Nature.1998,395:763-770.
13 Maeda K,Okubo K,Shimomura I,et al.cDNA cloning and expression of a novel adipose specific collagen-like factor,apM1(AdiPose Most abundant Gene transcript 1).Biochem Biophys Res Commun.1996,221:286-289.
14 Scherer PE,Williams S,Fogliano M,et al.A novel serum protein similar to Clq,produced exclusively in adipocytes.J Biol Chem.1995,270:26746-26749.
15 Steppan CM,Bailey ST,Bhat S,et al.The hormone resistin links obesity to diabetes.Nature.2001;409:307-312
16 Fischer-Posovszky P,Wabitsch M,Hochberg Z.Endocrinology of adipose tissue-an update.Horm Metab Res.2007,39:314-21.
17 Samal B,Sun Y,Stearns G,et al.Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.Mol Cell Biol.1994,14:1431-1437
18 Hammarstedt A,Pihlajamaki J,Rotter Sopasakis V,et al.Visfatin is an adipokine,but it is not regulated by thiazolidinediones.J Clin Endocrinol Metab.2006,91:1181-4.
19 McGlothlin JR,Gao L,Lavoie T,et al.Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor.Biochem Genet.2005,43:127-141.
20 Moschen AR,Kaser A,Enrich B,et al.Visfatin,an adipocytokine with proinflammatory and immunomodulating properties.J.Immunol.2007,178:1748-58.
21 Luk T,Malam Z,Marshall JC.Pre-B cell colony-enhancing factor(PBEF)/visfatin:a novel mediator of innate immunity.J Leukoc Biol.2008,83:804-16.
22 Adya R,Tan BK,Punn A,et al.Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways:novel insights into visfatin-induced angiogenesis.Cardiovasc Res.2008,78:356-65.
23 Kim SR,Bae SK,Choi KS,et al.Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2.Biochem Biophys Res Commun.2007,357:150-6.
24 Adya R,Tan BK,Chen J,Randeva HS.Nuclear Factor {kappa}B Induction by Visfatin in Human Vascular Endothelial Cells:Role in MMP-2/9 Production and Activation.Diabetes Care.2008,31:758-60.
25 Kim SR,Bae YH,Bae SK,et al.Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells.Biochim Biophys Acta.2008;1783:886-95
26 Tsiotra PC,Tsigos C,Yfanti E,et al.Visfatin,TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women.Horm Metab Res.2007,39:758-63.
27 Kase H,Hattori Y,Jojima T,et al.Globular adiponectin induces adhesion molecule expression through the sphingosine kinase pathway in vascular endothelial cells.Life Sci.2007,81:939-43.
28 Ajuwon KM,Spurlock ME.Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes.Am J Physiol Regul Integr Comp Physiol.2005,288:R1220-5
29 Spranger J,Verma S,G(o|¨)hring I,et al.Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells.Diabetes.2006,55:141-7.
30 Verma S,Li SH,Wang CH,et al.Resistin promotes endothelial cell activation:further evidence of adipokine-endothelial interaction.Circulation.2003,108:736-40.
31 Libby P.Changing concepts of atherosclerosis.J Intern Med.2001,247:349-58.
32 Weber C,Schober A,Zernecke A.Chemokines:Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease.Arterioscler.Thromb Vase Biol.2004,24:1997-2008.
33 Adya R,Tan BK,Chen J,Randeva HS.Pre-B cell colony enhancing factor(PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells:Role in visfatin-induced angiogenesis.Atherosclerosis.2008 Dec 3.[Epub ahead of print]
34 Bae YH,Bae MK,Kim SR,et al.Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis.Biochem Biophys Res Commun.2009,379:206-11.
35 Ognjanovic S,Tashima LS,Bryant-Greenwood GD.The effects of pre-B-cell colony-enhancing factor on the human fetal membranes by microarray analysis.Am J Obstet Gynecol.2003,189:1187-95.
36 Brentano F,Schorr O,Ospelt C,et al.Pre-B cell colony-enhancing factor/ visfatin,a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities.Arthritis Rheum.2007,56:2829-39
37 Lee WJ,Wu CS,Lin H,et al.Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway.Int J Obes(Lond).2009 Feb 17.[Epub ahead of print]
38 Oki K,Yamane K,Kamei N,et al.Circulating visfatin level is correlated with inflammation,but not with insulin resistance.Clin Endocrinol(Oxf).2007,67:796-800.
39 Seo JA,Jang ES,Kim BG,et al.Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women.Diabetes Res Clin Pract.2008,79:108-11.
40 Erten Y,Ebinc FA,Ebin(?)H,et al.The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients.Ren Fail.2008,30:617-23.
41 Lim SY,Davidson SM,Paramanathan AJ,et al.The novel adipocytokine visfatin exerts direct cardioprotective effects.J Cell Mol Med.2008,12:1395-403.
42 Goebeler M,Gillitzer R,Kilian K,et al.Multiple signaling pathways regulate NF-k B-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells.Blood.2001.97:46-55
43 Takaishi H,Taniguchi T,Takahashi A,et al.High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells.Biochem Biophys Res Comm.2003,305:122-8.
44 Choi EK,Park HJ,Ma JS,et al.LY294002 inhibits monocyte chemoattractant protein-1 expression through a phosphatidylinositol 3-kinase-independent mechanism.FEBS Lett.2004,559:141-4.
45 Shibata T,Imaizumi T,Tamo W,et al.Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells.Am J Physiol Heart Circ Physiol.2008,294:H750-63.
46 Gomaraschi M,Basilico N,Sisto F,et al.High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli.Biochim Biophys Acta.2005,1736:136-43.
47 Isoda K,Young JL,Zirlik A,et al.Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.Arterioscler Thromb Vase Biol.2006;269:611-7.
48 Shibata T,Imaizumi T,Tamo W,et al.Proteasome inhibitor MG-132 enhances the expression of interleukin-6 in human umbilical vein endothelial cells:Involvement of MAP/ERK kinase.Immunol Cell Biol.2002,80:226-30.
49 Saltiel AR,Kahn CR.Insulin signaling and the regulation of glucose and lipid metabolism.Nature.2001,414:799-806.
50 Fukuhara A,Matsuda M,Nishizawa M,et al.Visfatin:a protein secreted by visceral fat that mimics the effects of insulin.Science.2005;307:426-430.
51 Xie H,Tang SY,Luo XH,Huang J,Cui RR,Yuan LQ,Zhou HD,Wu XP,Liao EY.Insulin-like effects of visfatin on human osteoblasts.Calcif Tissue Int.2007,80:201-10.
52 Dahl TB,Yndestad A,Skjelland M,et al.Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque destabilization.Circulation.2007;115:972-80.
1 Eckel RH,York DA,Rossner S,et al.American Heart Association.Prevention conference Ⅶ:obesity,a worldwide epidemic related to heart disease and stroke:executive summary.Circulation.2004,110:2968-2975.
2 Lakka HM,Laaksonen DE,Lakka TA,et al.The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.JAMA.2002,288:2709-16.
3 Spiegelman BM,Choy L,Hotamisligil GS,Graves RA,Tontonoz P.Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes.J Biol Chem.1993,268:6823-6826.
4 Maeda K,Okubo K,Shimomura I,et al.Analysis of expression profile of genes in the human adipose tissue.Gene.1997,190:227-235.
5 Tedgui A,Mallat Z.Cytokines in atherosclerosis:pathogenic and regulatory pathways.Physiol Rev.2006,86:515-581.
6 Wu ZH,Zhao SP.Adipocyte:a potential target for the treatment of atherosclerosis.Med Hypotheses.2006,67:82-86.
7 Fukuhara A,Matsuda M,Nishizawa M,et al.Visfatin:a protein secreted by visceral fat that mimics the effects of insulin.Science.2005,307:426-430.
8 Samal B,Sun Y,Stearns G,et al.Cloning and characterization of the cDNA encoding a novel human pre-B-cell colonyenhancing factor.Mol Cell Biol.1994,14:1431-1437.
9 McGlothlin JR,Gao L,Lavoie T,et al.Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor.Biochem Genet.2005,43:127-141.
10 Moschen AR,Kaser A,Ludwiczek O,et al.Visfatin,an adipocytokine with proinflammatory and immunomodulating properties.J Immunol.2007,178:1748-58
11 Dahl TB,Yndestad A,Skjelland M,et al.Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque destabilization.Circulation,.2007,115:972-80.
12 Takebayashi K,Suetsugu M,Wakabayashi S,et al.Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.Metabolism,2007,56:451-8.
13 Fukuhara A,Matsuda M,Nishizawa M,et al.Retraction.Science,2007,318,565.
14 Levey AS,Coresh J,Balk E,et al.National Kidney Foundation.National Kidney Foundation practice guidelines for chronic kidney disease:evaluation,classification,and stratification.Ann Intern Med.2003,139:137-47.
15 The Expert Committee.Report of the Expert Committee on the diagnosis and classification of diabetes mellitus.Diabetes Care,1997,20:1183-1197.
16 Matthews DR,Hosker JP,Rudenski AS,et al.Homeostasis model assessment:insulin resistance and B-cell function from plasma glucose and insulin concentrations in man.Diabetologia.1985,28:412-419.
17 Ognjanovic S,Bao S,Yamamoto SY,et al.Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes.J Mol Endocrinol.2001,26:107-117.
18 Jia SH,Li Y,Parodo J,et al.Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.J Clin Invest,2004,113:1318-1327.
19 Koczan D,Guthke R,Thiesen HJ,et al.Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules.Eur J Dermatol.2005,15:251-257.
20 Nowell MA,Richards PJ,Fielding CA,et al.Regulation of pre-B cell colony-enhancing factor by e STAT-3-dependent interleukin-6 trans-signaling:implications in the pathogenesis of rheumatoid arthritis.Arthritis Rheum.2006,54:2084-95.
21 Adya R.,Tan BK,Punn A,et al.Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways:novel insights into visfatin-induced angiogenesis.Cardiovasc Res.2008,78:356-65.
22 van der Wal,A.C.,Becker,A.E.Atherosclerotic plaque rupture-pathologic basis of plaque stability and instability.Cardiovasc Res.1999,41:334-344.
23 Virmani R,Kolodgie FD,Burke AP,et al.Atherosclerotic plaque progression and vulnerability to rupture:angiogenesis as a source of intraplaque hemorrhage.Arterioscler Thromb Vase Biol.2005,25:2054-61.
24 Charo IF,Taubman MB.Chemokines in the pathogenesis of vascular disease.Circ Res.2004,95:858-66.
25 de Lemos JA,Morrow DA,Blazing MA,et al.Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes:results from the A to Z trial.J Am Coll Cardiol.2004,50,2117-24.
26 Yudkin JS,Kumari M,Humphries SE,Mohamed-Ali,V.Inflammation,obesity,stress and coronary heart disease:is interleukin-6 the link?Atherosclerosis.2000,148,209-14.
27 Woods A,Brull DJ,Humphries SE,Montgomery HE.Genetics of inflammation and risk of coronary artery disease:the central role of interleukin-6.Eur Heart J.2000,21:1574-83.
28 Hartford M,Wiklund O,Mattsson Hulten L,et al.C-reactive protein,interleukin-6,secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes.J Intern Med.2007,262,526-36.
29 Lindmark E,Diderholm E,Wallentin L,Siegbahn A.Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease:effects of an early invasive or noninvasive strategy.JAMA.2001,286:2107-13.
30 Matsumori A,Furukawa Y,Hashimoto T.Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction.J Mol Cell Cardiol.2007,29:419-23.
31 Gabriel AS,Martinsson A,Wretlind B,Ahnve S.IL-6 levels in acute and post myocardial infarction:their relation to CRP levels,infarction size,left ventricular systolic function,and heart failure.Eur J Intern Med.2004,15,523-8.
32 Hartford M,Wiklund O,Mattsson Hulten L,et al.CRP,interleukin-6,secretory phospholipase A2 group IIA,and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up.Int J Cardiol.2006,108,55-62.
33 Pagano C,Pilon C,Olivieri M,Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans.J Clin Endocrinol Metab.2006,91,3165-70.
34 Oki K,Yamane K,Kamei N,et al.Circulating visfatin level is correlated with inflammation,but not with insulin resistance.Clin Endocrinol(Oxf),2007,67,796-800.
35 Kowalska I,Straczkowski M,Nikolajuk A,et al.Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.Hum Reprod;2007,22,1824-9.
36 Lopez-Bermejo A,Chico-Julia B,Fernandez-Balsells M,et al.Serum visfatin Increases With Progressive {beta}-Cell Deterioration.Diabetes.2006,55:2871-5.
37 Chen MP,Chung FM,Chang DM,et al.Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with Type 2 diabetes mellitus.J Clin Endocrinol Metab.2006,91:295-299.
38 Wang P,van Greevenbroek MM,Bouwman FG,et al.The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile.Pflugers Arch.2007,454971-6.
39 Sun G,Bishop J,Khalili S,et al.Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men.Am J Clin Nutr.2007,85:399-404.
1 Fantuzzi G.Adipose tissue,adipokines,and inflammation.J Allergy Clin Immunol.2005,115:911-919.
2 Kahn BB,Flier JS.Obesity and insulin resistance.J Clin Invest.2000,106:473-481.
3 Giorgino F,Laviola L,Eriksson JW.Regional differences of insulin action in adipose tissue:insights from in vivo and in vitro studies.Acta Physiol Scand.2005,183:13-30.
4 Fukuhara A,Matsuda M,Nishizawa M,et al.Visfatin:a protein secreted by visceral fat that mimics the effects of insulin.Science.2005,307:426-430.
5 Samal B,Sun Y,Stearns G,et al.Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.Mol Cell Biol.1994,14:1431-1437.
6 Martin PR,Shea RJ,Mulks MH.Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence.J Bacteriol.2001,183:1168-1174.
7 Wang T,Zhang X,Bheda P,et al.Structure of Nampt/PBEF/visfatin,a mammalian NAD+ biosynthetic enzyme.Nat Struct Mol Biol.2006,13:661-662.
8 Kim MK,Lee JH,Kim,H.et al.Crystal structure of visfatin/pre-B cell colonyenhancing factor 1/nicotinamide phosphoribosyltransferase,free and in complex with the anti-cancer agent FK-866.J Mol Biol.2006,362:66-77.
9 Jia SH,Li Y,Parodo J,et al.Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.J Clin Invest.2004,113:1318-1327.
10 Ognjanovic S,Bao S,Yamamoto SY,et al.Genomic organization of the gene coding for human pre--B-cell colony enhancing factor and expression in human fetal membranes.J Mol Endocrinol.2001,26:107—117.
11 Haider DG,Schaller G,Kapiotis S,et al.The release of the adipocytokine visfatin is regulated by glucose and insulin.Diabetologia.2006,49:1909-14.
12 Pfutzner A,Forst T.Comment on:Haider DG,Schaller G,Kapiotis S,et al.The release of the adipocytokine visfatin is regulated by glucose and insulin.Diabetologia.49,1909-1914.Diabetologia.2006,49:2795.
13 MacLaren R,Cui W,Cianflone K.Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes.Diabetes Obes Metab.2007,9:490-497.
14 Haider DG,Mittermayer F,Schaller G.et al.Free fatty acids normalize a rosiglitazone-induced visfatin release.Am J Physiol Endocrinol Metab.2006,291:E885-E890.
15 Pagano C,Pilon C,Olivieri M,et al.Reduced plasma visfatin/pre-B cell colonyenhancing factor in obesity is not related to insulin resistance in humans.J Clin Endocrinol Metab.2006,91:3165-70.
16 Kralisch S,Klein J,Lossner U,et al.Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes.Am J Physiol Endocrinol Metab.2005,289:E586-90.
17 Hammarstedt A,Pihlajamaki J,Rotter Sopasakis V,et al.Visfatin is an adipokine,but it is not regulated by thiazolidinediones.J Clin Endocrinol Metab.2006,91:1181-4.
18 Varma V,Yao-Borengasser A,Rasouli,N.et al.Human visfatin expression:relationship to insulin sensitivity,intramyocellular lipids,and inflammation.J Clin Endocrinol Metab.2007,92:666-672.
19 Choi KC,Ryu OH,Lee KW,et al.Effect of PPAR-alpha and-gamma agonist on the expression of visfatin,adiponectin,and TNF-alpha in visceral fat of OLETF rats.Biochem Biophys Res Commun.2005,336:747-753.
20 Choi KC,Lee,SY,Yoo HJ,et al.Effect of PPAR-δ agonist on the expression of visfatin,adiponectin,and resistin in rat adipose tissue and 3T3-L1 adipocytes.Biochem Biophys Res Commun.2007,357:62-67.
21 Haider DG,Schindler K,Schaller G,et al.Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding.J Clin Endocrinol Metab.2006,91:1578-81.
22 Manco M,Fernandez-Real JM,Equitani F,et al.Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women.J Clin Endocrinol Metab.2007,92:483-490.
23 Krzyzanowska K,Mittermayer F,Krugluger W,et al.Increase in visfatin after weight loss induced by gastroplastic surgery.Obesity.2006,14:1886-1889.
24 Frydelund-Larsen L,Akerstrom T,Nielsen S,et al.Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise.Am J Physiol Endocrinol Metab.2007,292:E24-E31.
25 Haider DG,Pleiner J,Francesconi M,et al.Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes.J Clin Endocrinol Metab.2006,91:4702-4704.
26 Kralisch S,Klein J,Lossner U.et al.Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.J Endocrinol.2005,185:R1-R8.
27 Ye SQ,Simon BA,Maloney JP,et al.Pre-B cell colony-enhancing factor as a potential novel biomarker in acute lung injury.Am J Respir Care Med.2004,171:361-70.
28 Iqbal J,Zaidi M.TNF regulates cellular NAD+ metabolism in primary macrophages.Biochem Biophys Res Commun.2006,342:1312-1318.
29 Ando H,Yanagihara H,Hayashi Y,et al.Rhythmic messenger ribonucleic acid expression of clock genes and adipocytokines in mouse visceral adipose tissue.Endocrinology.2005,146:5631-6.
30 Bae SK,Kim SR,Kim JG,et al.Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1.FEBS Lett.2006,580:4105-13.
31 Xie H,Tang SY,Luo XH,et al.Insulin-like effects of visfatin on human osteoblasts.Calcif Tissue Int.2007,80:201-210.
32 Dahl TB,Yndestad A,Skjelland M,et al.Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque destabilization.Circulation.2007,115:972-80.
33 Fukuhara A,Matsuda M,Nishizawa M.et al.Retraction:Visfatin:a protein secreted by visceral fat that mimics the effects of insulin.Science,2007,318:565.
34 Berndt J,Kloting N,Kralisch S,et al.Plasma visfatin concentrations and fat depotspecific mRNA expression in humans.Diabetes.2005,54:2911-2916.
35 Kloting N,Kloting I.Visfatin:gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats.Biochem Biophys Res Commun.2005,332:1070-2.
36 Kralisch S,Klein J,Lossner U,et al.Isoproterenol,TNFalpha,and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytes.Mol Cell Endocrinol,2005,240:43-49.
37 Kitani T.et al.Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor.FEBS Lett.2003,544,74-78.
38 Lopez-Bermejo A,Chico-Julia B,Fernandez-Balsells M,et al.Serum visfatin Increases With Progressive {beta}-Cell Deterioration.Diabetes.2006,55:2871-5.
39 Schindler K,Haider D,Wolzt M,et al.Impact of anti-retroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects.Eur J Clin Invest.2006,36:640-6.
40 Krzyzanowska K,Krugluger W,Mittermayer F,et al.Increased visfatin concentrations in women with gestational diabetes mellitus.Clin Sci(Lond).2006,110:605-9.
41 Dogru T,Sonmez A,Tasci I,et al.Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.Diabetes Res Clin Pract.2007,76:24-29.
42 Chen MP,Chung FM,Chang DM,et al.Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with Type 2 diabetes mellitus.J Clin Endocrinol Metab.2006,91:295-299
43 Lewandowski KC,Stojanovic N,Press M,et al.Elevated serum levels of visfatin in gestational diabetes:a comparative study across various degrees of glucose tolerance.Diabetologia.2007,50:1033-1037.
44 Chan TF,Chen YL,Lee CH,et al.Decreased plasma visfatin concentrations in women with gestational diabetes mellitus.J Soc Gynecol Invest.2006,13:364-367.
45 Telejko B,Kuzmicki M,Zonenberg A,et al.Visfatin in gestational diabetes:serum level and mRNA expression in fat and placental tissue.Diabetes Res Clin Pract.2009,84:68-75.
46 Chan TF,Chenb Sc YL,Chen HH,et al.plasma visfatin concentrations in women with polycystic ovary syndrome.Fertil Steril.2007,88,401-405.
47 Tan BK,Chen J,Digby J E,et al.Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome:parallel increase in plasma visfatin.J Clin Endocrinol Metab.2006,91:5022-5028.
48 Moschen AR,Kaser A,Enrich B,et al.Visfatin,an adipocytokine with proinflammatory and immunomodulating properties.J Immunol.2007,178:1748-58.
49 Koczan D,Guthke R,Thiesen HJ,et al.Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules.Eur.Dermatol.2005,15:251-257.
50 Garcia JG.and Moreno VL.Genomic insights into acute inflammatory lung injury.Am J Physiol Lung Cell Mol Physiol.2006,291:L1 113-L1117.
51 Ye SQ,Zhang LQ,Adyshev D,et al.Pre-Bcell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation.Microvasc Res.2005,70:142-151.
52 Nowell MA,Richards PJ,Fielding CA,et al.Regulation of pre-B cell colonyenhancing factor by STAT-3-dependent interleukin-6 trans-signaling:implications in the pathogenesis of rheumatoid arthritis.Arthritis Rheum.2006,54:2084-2095.
53 Otero M,Lago R,Gomez R,et al.Changes in plasma levels of fat-derived hormones adiponectin,leptin,resistin and visfatin in patients with rheumatoid arthritis.Ann Rheum Dis.2006,65:1198-1201.
54 Oki K,Yamane K,Kamei N,et al.Circulating visfatin level is correlated with inflammation,but not with insulin resistance.Clin Endocrinol.2007,67:796-800.
55 Cheng KH,Chu CS,Lee KT,et al.Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease.Int J Obes(Lond)2008,32:268-74.
56 Rongvaux A,Shea RJ,Mulks MH,et al.Pre-B-cell colony-enhancing factor,whose expression is up-regulated in activated lymphocytes,is a nicotinamide phosphoribosyltransferase,a cytosolic enzyme involved in NAD biosynthesis.Eur J Immunol.2002,32:3225-3234.
57 Revollo JR,K(o|¨)rner A,Mills KF,et al.Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme.Cell Metab.2007,6:363-75.
58 van der Ver E,Nong Z,0 Neil C,et al.Pre-B—cell colony—enhancing factor regulates NAD-dependent protein deacetylase acivity and promotes Vascular Smooth Muscle Cell maturation.Circ Res.2005,97:25—34.
59 Zhang J,Dawson VL,Dawson TM,Snyder SH.Nitric oxide activation of poly(ADP-ribose)synthetase in neurotoxicity.Science.1994,263:687-689.
60 Revollo J R,Grimm A A,Imai S.The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells.J Biol Chem.2004,279:50754-50763.
61 Ognjanovic S,Ku TL,Bryant-Greenwood GD.Pre-B-cell colony enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium.Am J Obstet Gynecol.2005,193:273-82.
62 Kendal-Wright CE,Hubbard D,Bryant-Greenwood GD.Chronic stretching of amniotic epithelial cells increases pre-B cell colony-enhancing factor(PBEF/visfatin)expression and protects them from apoptosis.Placenta.2008,29:255-65.
63 Adya R,Tan BK,Punn A,et al.Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways:novel insights into visfatin-induced angiogenesis.Cardiovasc Res.2008,78:356-65.
64 van der Veer E,Ho C,O'Neil C,et al.Extension of human cell lifespan by nicotinamide phosphoribosyltransferase.J Biol Chem.2007,282:10841-10845.
65 Lim SY,Davidson SM,Paramanathan AJ,et al.The novel adipocytokine visfatin exerts direct cardioprotective effects.J Cell Mol Med.2008,12:1395-403.
66 Pillai JB,Isbatan A,Imai S,Gupta MP.Poly(ADP-ribose)polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2a deacetylase activity.J Biol Chem.2005,280:43121-43130.
67 Borradaile NM,Pickering JG.Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment.Aging Cell.2009 Mar 13.[Epub ahead of print]
1 Trujillo ME,Scherer PE.Adipose tissue-derived factors:impact on health and disease.Endocr Rev.2006,27:762-778.
2 Lago F,Di(?)guez C,G(?)mez-Reino J,Gualillo O.The emerging role of adipokines as media tots of inflammation and immune responses.Cytokine Growth Factor Rev.2007,18:313-325.
3 Wang Y,et al.Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin.Potential role in the modulation of its insulin-sensitizing activity.J Biol Chem.2002,277:19521-19529.
4 Pajvani UB,Du X,Combs TP,et al.Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin.Implications for metabolic regulation and bioactivity.J Biol Chem.2003,278:9073-9085,.
5 Neumeier M,et al.Different effects of adiponectin isoforms in human monocytic cells.J Leukoc Biol.2006,79:803-808.
6 Aso Y,Yamamoto R,Wakabayashi S,et al.Comparison of serum high-molecular weight(HMW) adiponectin with total adiponectin concentrations in Type 2 diabetic patients with coronary artery dise,ase using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin.Diabetes 2006,55:1954-1960,
7 Yamauchi T,Kamon J,Ito Y,et al.Cloning of adiponectin receptors that mediate antidiabetic metabolic effects.Nature,2003,423:762-769.
8 Hug C,Wang J,Ahmad NS,et al.T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin.Proc Natl Acad Sci USA.2004,101:10308-10313.
9 Kadowaki T,Yamauchi T.Adiponectin and adiponectin receptors.Endocr Rev.2005,26:439-451.
10 Szmitko PE,Wang CH,Weisel RD,et al.New markers of inflammation and endothelial cell activation.Circulation.2003,108:1917-1923.
11 Chen H,Montagnani M,Funahashi T,et al.Adiponectin stimulates production of nitric oxide in vascular endothelial cells.J Biol Chem 2003.278:45021-45026,
12 Motoshima H,Wu X,Mahadev K,Goldstein BJ.Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL.Biochem Biophy sCommun 2004,315:264-271.
13 Ouedraogo R,Gong Y,Berzins B,et al.Adiponectin deficiency increases leukocyte endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo.J Clin Invest.2007,117:1718-1726.
14 Ouchi N,Kihara S,Arita Y,et al.Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin.Circulation.1999,100:2473-2476.
15 Ouchi N,Kihara S,Arita Y,et al.Adipocyte-derived plasma protein,adiponectin,suppresses lipid accumulation and class A scavenger receptor expression in human monocytederived macrophages.Circulation 2001,103:1057-1063.
16 Arita Y,Kihara S,Ouchi N,et al.Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell.Circulation.2002,105:2893-2898.
17 Kumada M,Kihara S,Sumitsuji S,et al.Association of hypoadiponectinemia with coronary artery disease in men.Arterioscler Thromb Vase Biol 2003,23:85-89.
18 Sell H,Dietze-Schroeder D,Eckardt K,Eckel J.Cytokine secretion by human adipocytes is differentially regulated by adiponectin,AICAR,and troglitazone.Biochem Biophys Res Commun.2006,343:700-706.
19 Okamoto Y,Kihara S,Ouchi N,et al.Adiponectin reduces atherosclerosis in apolipoprotein E-deflcient mice.Circulation 2002,106:2767-70.
20 Li CJ,Sun HW,Zhu FL,et al.Local adiponectin treatment reduces atherosclerotic plaque size in rabbits.J Endocrinol.2007,193:137-45.
21 Kato H,Kashiwagi H,Shiraga M,et al.Adiponectin acts as an endogenous antithrombotic factor.Arterioscler Thromb Vasc Biol 2006,26:224-230.
22 Date H,Imamura T,Ideguchi T,et al.Adiponectin produced in coronary circulation regulates coronary flow reserve in nondiabetic patients with angiographically normal coronary arteries.Clin Cardiol.2006,29:211-214.
23 Takano H,Kodama Y,Kitta Y,et al.Transcardiac adiponectin gradient is independently related to endothelial vasomotor function in large and resistance coronary arteries in humans.Am J Physiol Heart Circ Physiol.2006,291:H2641-H2646.
24 Ouchi N,Kihara S,Arita Y,et al.Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin.Circulation.1999,100:2473-6.
25 Kumada M,Kihara S,Sumitsuji S,et al.Association of hypoadiponectinemia with coronary artery disease in men.Arterioscler Thromb Vase Biol.2003,23:85-9.
26 Nakamura Y,Shimada K,Fukuda D,Shimada Y,Ehara S,Hirose M,et al.Implications of plasma concentrations of adiponectin in patients with coronary artery disease.Heart.2004,90:528-33.
27 Pischon T,Girman CJ,Hotamisligil GS,et al.Plasma adiponectin levels and risk of myocardial infarction in men.JAMA.2004,291:1730-1737.
28 Kojima S,Funahashi T,Sakamoto T,et al.The variation of plasma concentrations of a novel,adipocyte-derived protein,adiponectin,in patients with acute myocardial infarction.Heart.2003,89:667.
29 Otsuka F,Sugiyama S,Kojima S,et al.Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease.J Am Coll Cardiol.2006,48:1155-1162.
30 Cavusoglu E,Ruwende C,Chopra V,et al.Adiponectin is an independent predictor of all cause mortality,cardiac mortality,and myocardial infarction in patients presenting with chest pain.Eur Heart J.2006,27:2300-2309.
31 Lindsay RS,Resnick HE,Zhu J?et al.Adiponectin and coronary heart disease:the Strong Heart Study.Arterioscler Thromb Vase Biol.2005,25:el5-e6.
32 Lawlor DA,Davey Smith G,Ebrahim S,et al.Plasma adiponectin levels are associated with insulin resistance,but do not predict future risk of coronary heart disease in women.J Clin Endocrinol Metab.2005,90:5677-83.
33 Sattar N,Wannamethee G,Sarwar N,et al.Adiponectin and coronary heart disease:a prospective study and meta-analysis.Circulation.2006,114:623-9.
34 Beltowski J.Leptin and atherosclerosis.Atherosclerosis.2006,189:47-60.
35 Sinha MK,Opentanova I,Ohannesian JP,et al.Evidence of free and bound leptin in human circulation.Studies in lean and obese subjects and during short-term fasting.J Clin Invest.1996,98:1277-1282.
36 oleman RA,Herrmann TS.Nutritional regulation of leptin in humans.Diabetologia.1999,42:639-646.
37 Fried SK,Ricci MR,Russell CD,Laferrere B.Regulation of leptin production in humans.J Nutr.2000,130:3127S-3131S.
38 Matsui H,Motooka M,Koike H,et al.Ischemia/reperfusion in rat heart induces leptin and leptin receptor gene expression.Life Sci.2007,80:672-680.
39 Rajapurohitam V,Javadov S,Purdham DM,et al.An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin-1.J Mol Cell Cardiol.2006,41:265-274.
40 Fei H,Okano HJ,Li C,Lee GH,et al.Anatomic localization of alternatively spliced leptin receptors(ob-R)in mouse brain and other tissues.Proc Natl Acad Sci USA.1997,94:7001-7005.
41 Ge H,Huang L,Pourbahrami T,Li C.Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo.J Biol Chem.2002,277:45898-45903
42 Bjorbaek C,Uotani S,da Silva B,Flier JS.Divergent signaling capacities of the long and short isoforms of the leptin receptor.J Biol Chem.1997,272:32686-32695.
43 Li L,Mamputu JC,Wiernsperger N,Renier G.Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin:inhibitory effect of metformin.Diabetes.2005,54:2227-2234.
44 Oda A,Taniguchi T,Yokoyama M.Leptin stimulates rat aortic smooth muscle cell proliferation and migration.Kobe J Med Sci.2001,47:141-150.
45 Nakata M,Yada T,Soejima N,Maruyama I.Leptin promotes aggregation of human platelets via the long form of its receptor.Diabetes.1999,48:426-429.
46 Maruyama I,Nakata M,Yamaji K.Effect of leptin in platelet and endothelial cells.Obesity and arterial thrombosis.Ann N Y Acad Sci.2000,902:315-31
47 Bouloumie A,Marumo T,Lafontan M,Busse R.Leptin induces oxidative stress in human endothelial cells.FASEB J.1999,13:1231-1238.
48 Yamagishi SI,Edelstein D,Du XL,et al.Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by in-creasing fatty acid oxidation via protein kinase A.J Biol Chem,2001,276:25096-25100.
49 Quehenberger P,Exner M,Sunder-Plassmann R,et al.Leptin induces endothelin-1 in endothelial cells in vitro.Circ Res.2002,90:711-718.
50 Park HY,Kwon HM,Lim HJ,et al.Potential role of leptin in angiogenesis:leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro.Exp Mol Med.2001,33:95-102.
51 Nakata M,Yada T,Soejima N,et al.Leptin promotes aggregation of human platelets via the long form of its receptor.Diabetes,1999,48:426-429.
52 Konstantinides S,Schafer K,Koschnick S,et al.Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity.J Clin Invest,2001,108:1533-1540.
53 Bodary PF,Gu S,Shen Y,et al.Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice.Arterioscler Thromb Vase Biol.2005,25:e119-e122
54 Wu KK,Wu TJ,Chin J,et al.Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor.Atherosclerosis.2005,181:251-259.
55 Ramsay JE,Ferrell WR,Crawford L,et al.Divergent metabolic and vascular phenotypes in pre-eclampsia and intrauterine growth restriction:relevance of adiposity.J Hypertens.2004,22:2177-2183.
56 Sierra-Johnson J,Romero-Corral A,L(?)pez-Jim(?)nez F,et al.Relation of increased leptin con-centrations to history of myocardial infarction and stroke in the United States population.Am J Cardiol,2007,100:234-239.
57 Iribarren C,Husson G,Go AS,et al.Plasma leptin levels and coronary artery calcification in older adults.J Clin Endocrinol Metab.2007,92:729-732.
58 Sattar N,Wannamethee G,Sarwair N,Leptin and coronary heart disease:prospective study and systematic review.J Am Coll Cardiol.2009,53:167-75.
59 Hoefle G,Saely CH,Risch L,et al.Leptin,leptin soluble receptor and coronary atherosclerosis.Eur J Clin Invest.2007,37:629-36.
60 Lawlor DA,Smith GD,Kelly A,etal.Leptin and coronary heart disease risk:prospective case control study of British women.Obesity.2007,15:1694-701.
61 Steppan CM,Bailey ST,Bhat S,et al.The hormone resistin links obesity to diabetes.Nature.2001,409:307-312.
62 Banerjee RR,Lazar MA.Dimerization of resistin and resistin-like molecules is determined by a single cysteine.J Biol Chem.2001,276:25970-25973.
63 Steppan CM,Bailey ST,Bhat S,et al.The hormone resistin links obesity to diabetes.Nature.2001,409:307-312.
64 Verma S,Li SH,Wang CH,et al.Resistin promotes endothelial cell activation:further evidence of adipokine-endothelial interaction.Circulation.2003,108:736-740.
65 Kawanami D,Maemura K,Takeda N,et al.Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells:a new insight into adipocytokine-endothelial cell interactions.Biochem Biophys Res Commun.2004,314:415-419.
66 Kougias P,Chai H,Lin PH,et al.Adipocyte derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries.J Vase Surg.2005.41:691-698.
67 Jung HS,Park KH,Cho YM,et al.Resistin is secreted from macrophages in atheromas and promotes atherosclerosis.Cardiovasc Res.2006,69:76-85.
68 Calabro P,Samudio I,Willerson JT,et al.Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways.Circulation.2004,110:3335-3340.
69 Bokarewa M,Nagaev I,Dahlberg L,et al.Resistin,an adipokine with potent proinflammatory properties.J Immunol.2005,174:5789—5795.
70 Burnett MS,Lee CW,Kinnaird TD,et al.The potential role of resistin in atherogenesis.Atherosclerosis.2005,182:241-248.
71 Gentile MT,Vecchione C,Marino G,et al.Resistin impairs insulin-evoked vasodilation.Diabetes.2008,57:577-83.
72 Reilly MP,Lehrke M,Wolfe ML,et al.Resistin is an inflammatory marker of atherosclerosis in humans.Circulation.2005,111:932-9.
73 Kunnari A,Ukkola O,Paivansalo M,et al.High plasma resistin levels is associated with enhanced highly sensitive C-reactive protein and leukocytes.J Clin Endocrinol Metab.2006,91:2755-2760.
74 Lubos E,Messow CM,Schnabel R,et al.Resistin,acute coronary syndrome and prognosis results from the AtheroGene study.Atherosclerosis.2007,193:121-128.
75 On YK,Park HK,Hyon MS,et al.Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients.Circ J.2007,71:868-73.
76 Liang KW,Sheu WH,Lee WL,et.Decreased circulating protective adiponectin level is associated with angiographic coronary disease progression in patients with angina pectoris.Int J Cardiol,2008,129:76-80.
77 Pischon T,Bamberger CM,Kratzsch J,et al.Association of plasma resistin levels with coronary heart disease in women.Obes Res.2005,13:1764-71.
78 Fukuhara A,Matsuda M,Segawa K,et al.Visfatin:a protein secreted by visceral fat that mimics the effects of insulin.Science,2005,307:426-430.
79 JiaSH,LiY,Parodo J,et al.Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.J Clin Invest.2004,113: 1318-1327.
80 Samal B,Sun Y,Stearns G,et al.Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.Mol Cell Biol.1994,14:1431-1437.
81 Moschen AR,Kaser A,Enrich B,et al.Visfatin,an adipocytokine with proinflammatory and immunomodulating properties.J Immunol.2007,178:1748-58.
82 Dahl TB,Yndestad A,Skjelland M,et al.Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque de-stabilization.Circulation.2007,115:972-980.
83 Adya R.,Tan BK,Punn A,et al.Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways:novel insights into visfatin-induced angiogenesis.Cardiovasc Res.2008,78:356-65.
84 Bae YH,Bae MK,Kim SR,Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis.Biochem Biophys Res Commun.2009,379:206-11.
85 Adya R,Tan BK,Chen J,Randeva HS.Nuclear Factor {kappa}B Induction by Visfatin in Human Vascular Endothelial Cells:Role in MMP-2/9 Production and Activation.Diabetes Care.2008,31:758-60.
86 Kim SR,Bae YH,Bae SK,et al.Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells.Biochim Biophys Acta.2008,1783:886-95.
87 Cheng KH,Chu CS,Lee KT,et al.Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease.Int J Obes(Lond).2008,32:268-74.
88 Choi KM,Lee JS,Kim EJ,et al.Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease.Eur J Endocrinol.2008,158:203-7.
89 Tatemoko K,Hosoya M,Habata Y,et al.Isolation and characterization of a novel endogenous peptide ligand for the human APJ mceptor.Biochem Biophys Res Commun.1998,251:471-476.
90 Kawamata Y,Habata Y,Fukusumi S,et al.Molecular properties of apelin:tissue distribution and receptor binding.Biochina Biophys Acta.2001,1538:162-171.
91 Zhong JC,Yu XY,Huang Y,et al.Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice.Cardiovasc Res.2007,74:388-395.
92 Kunduzova O,Alet N,Delesque-Touchard N,et al.Apelin/APJ signaling system:a potential link between adipose tissue and endothelial angiogenic processes.FASEB J.2008,22:4146-53.
93 Chun HJ,Ali ZA,Kojima Y,Kundu RK,et al.Apelin signaling antagonizes Ang Ⅱ effects in mouse models of atherosclerosis.J Clin Invest.2008,118:3343-54.
94 Hashimoto T,Kihara M,Imai N,et al.Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis.Am J Pathol,2007,171:1705-12.
95 Malyszko J,Malyszko JS,Pawlak K.Apelin,a novel adipocytokine,in relation to endothelial function and inflammation in kidney allograft recipients.Transplant Proc.2008,40:3466-9.
96 Schaffler A,Neumeier M,Herfarth H,et al.Genomic structure of human omentin,a new adipocytokine expressed in omental adipose tissue.Biochim Biophys Acta.2005,1732:96-102.
97 Yang RZ,Lee MJ,Hu H,et al.Identification of omentin as a novel depot-specific adipokine in human adipose tissue:possible role in modulating insulin action.Am J Physiol Endocrinol Metab.2006,290:El253-61.
98 De Souza CM,Yang RZ,Lee MJ,et al.Omentin plasma levels and gene expression are decreased in obesity.Diabetes,2007,56:1655-1661.
99 Wittamer V,Franssen JD,Vulcano M Specific recruitment of antigen-presenting cells by chemerin,a novel processed ligand from human inflammatory fluids.J Exp Med.2003,198:977-85.
100 Zabel BA,Zuniga L,Ohyama T,et al.Chemoattractants,extracellular proteases,and the integrated host defense response.Exp Hematol.2006,34:1021-32.
101 Goralski KB,McCarthy TC,Hanniman EA,et al:Chemerin:a novel adipokine that regulates adipogenesis and adipocyte metabolism.J Biol Chem.2007,282:28175-28188.
102 Ruan H,Lodish HF:Insulin resistance in adipose tissue:direct and indirect effects of tumor necrosis factor-α.Cytokine Growth Factor Rev.2003,14:447-455.
103 Wang B,Trayhurn P.Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture.Pflugers Arch.2006,452:418-427.
104 Kaser S,Kaser A,Sandhofer A,et al.Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro.Biochem Biophys Res Commun.2003,309:286-290.
105 Hector J,Schwarzloh B,Goehring J,et al:TNF-alpha alters visfatin and adiponectin levels in human fat.Horm Metab Res.2007,39:250-255.
106 Lo J,Bernstein LE,Canavan B,et al.Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome.Am J Physiol Endocrinol Metab.2007,293:E102-E109.
107 Kralisch S,Bluher M,Paschke R,et al.Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome.Mini Rev Med Chem.2007,7:39-45.
108 Mazurek T,Zhang L,Zalewski A,et al.Human epicardial adipose tissue is a source of inflammatory mediators.Circulation.2003,108:2460-2466.
109 Aso Y.Plasminogen activator inhibitor(PAI)-1 in vascular inflammation and thrombosis.Front Biosci.2007,12:2957-2966.
2 Braunersreuther V,Mach F,Steffens S.The specific role of chemokines in atherosclerosis.Thromb Haemost.2007,97:714-21.
3 Naka T,Nishimoto N,Kishimoto T.The paradigm of IL-6:from basic science to medicine.Arthritis Res.2002,3:S233-S242.
4 Lotz M:Interleukin-6.Cancer Invest.1993,11:732-742.
5 Yudkin JS,Kumari M,Humphries SE,Mohamed-Ali V.Inflammation,obesity,stress and coronary heart disease:is interleukin-6 the link? Atherosclerosis.2002.148:209-14.
6 Eckel RH,York DA,R(o|¨)ssner S,et al.American Heart Association.Prevention conference Ⅶ:obesity,a worldwide epidemic related to heart disease and stroke:executive summary.Circulation.2004,110:2968-2975.
7 Skurk T,Alberti-Huber C,Herder C,Hauner H.Relationship between adipocyte size and adipokine expression and secretion.J Clin Endocrinol Metab.2007,92:1023-1033.
8 Yudkin,J.S.Inflammation,obesity,and the metabolic syndrome.Horm Metab Res.2007,39:707-9.
9 Hotamisligil GS,Shargill NS,Spiegelman BM.Adipose expression of tumor necrosis factor-α:direct role in obesity- linked insulin resistance.Science.1993,259:87-91.
10 Fain JN,Madan AK,Hiler ML,et al.Comparison of the release of adipokines by adipose tissue,adipose tissue matrix,and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans.Endocrinology.2004,145:2273-2282.
11 Shimomura I,Funahashi T,Takahashi M,et al.Enhanced expression of PAI-1 in visceral fat:possible contributor to vascular disease in obesity.Nat Med.1996,2:800-803.
12 Friedman JM,Halaas JL.Leptin and the regulation of body weight in mammals.Nature.1998,395:763-770.
13 Maeda K,Okubo K,Shimomura I,et al.cDNA cloning and expression of a novel adipose specific collagen-like factor,apM1(AdiPose Most abundant Gene transcript 1).Biochem Biophys Res Commun.1996,221:286-289.
14 Scherer PE,Williams S,Fogliano M,et al.A novel serum protein similar to Clq,produced exclusively in adipocytes.J Biol Chem.1995,270:26746-26749.
15 Steppan CM,Bailey ST,Bhat S,et al.The hormone resistin links obesity to diabetes.Nature.2001;409:307-312
16 Fischer-Posovszky P,Wabitsch M,Hochberg Z.Endocrinology of adipose tissue-an update.Horm Metab Res.2007,39:314-21.
17 Samal B,Sun Y,Stearns G,et al.Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.Mol Cell Biol.1994,14:1431-1437
18 Hammarstedt A,Pihlajamaki J,Rotter Sopasakis V,et al.Visfatin is an adipokine,but it is not regulated by thiazolidinediones.J Clin Endocrinol Metab.2006,91:1181-4.
19 McGlothlin JR,Gao L,Lavoie T,et al.Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor.Biochem Genet.2005,43:127-141.
20 Moschen AR,Kaser A,Enrich B,et al.Visfatin,an adipocytokine with proinflammatory and immunomodulating properties.J.Immunol.2007,178:1748-58.
21 Luk T,Malam Z,Marshall JC.Pre-B cell colony-enhancing factor(PBEF)/visfatin:a novel mediator of innate immunity.J Leukoc Biol.2008,83:804-16.
22 Adya R,Tan BK,Punn A,et al.Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways:novel insights into visfatin-induced angiogenesis.Cardiovasc Res.2008,78:356-65.
23 Kim SR,Bae SK,Choi KS,et al.Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2.Biochem Biophys Res Commun.2007,357:150-6.
24 Adya R,Tan BK,Chen J,Randeva HS.Nuclear Factor {kappa}B Induction by Visfatin in Human Vascular Endothelial Cells:Role in MMP-2/9 Production and Activation.Diabetes Care.2008,31:758-60.
25 Kim SR,Bae YH,Bae SK,et al.Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells.Biochim Biophys Acta.2008;1783:886-95
26 Tsiotra PC,Tsigos C,Yfanti E,et al.Visfatin,TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women.Horm Metab Res.2007,39:758-63.
27 Kase H,Hattori Y,Jojima T,et al.Globular adiponectin induces adhesion molecule expression through the sphingosine kinase pathway in vascular endothelial cells.Life Sci.2007,81:939-43.
28 Ajuwon KM,Spurlock ME.Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes.Am J Physiol Regul Integr Comp Physiol.2005,288:R1220-5
29 Spranger J,Verma S,G(o|¨)hring I,et al.Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells.Diabetes.2006,55:141-7.
30 Verma S,Li SH,Wang CH,et al.Resistin promotes endothelial cell activation:further evidence of adipokine-endothelial interaction.Circulation.2003,108:736-40.
31 Libby P.Changing concepts of atherosclerosis.J Intern Med.2001,247:349-58.
32 Weber C,Schober A,Zernecke A.Chemokines:Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease.Arterioscler.Thromb Vase Biol.2004,24:1997-2008.
33 Adya R,Tan BK,Chen J,Randeva HS.Pre-B cell colony enhancing factor(PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells:Role in visfatin-induced angiogenesis.Atherosclerosis.2008 Dec 3.[Epub ahead of print]
34 Bae YH,Bae MK,Kim SR,et al.Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis.Biochem Biophys Res Commun.2009,379:206-11.
35 Ognjanovic S,Tashima LS,Bryant-Greenwood GD.The effects of pre-B-cell colony-enhancing factor on the human fetal membranes by microarray analysis.Am J Obstet Gynecol.2003,189:1187-95.
36 Brentano F,Schorr O,Ospelt C,et al.Pre-B cell colony-enhancing factor/ visfatin,a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities.Arthritis Rheum.2007,56:2829-39
37 Lee WJ,Wu CS,Lin H,et al.Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway.Int J Obes(Lond).2009 Feb 17.[Epub ahead of print]
38 Oki K,Yamane K,Kamei N,et al.Circulating visfatin level is correlated with inflammation,but not with insulin resistance.Clin Endocrinol(Oxf).2007,67:796-800.
39 Seo JA,Jang ES,Kim BG,et al.Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women.Diabetes Res Clin Pract.2008,79:108-11.
40 Erten Y,Ebinc FA,Ebin(?)H,et al.The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients.Ren Fail.2008,30:617-23.
41 Lim SY,Davidson SM,Paramanathan AJ,et al.The novel adipocytokine visfatin exerts direct cardioprotective effects.J Cell Mol Med.2008,12:1395-403.
42 Goebeler M,Gillitzer R,Kilian K,et al.Multiple signaling pathways regulate NF-k B-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells.Blood.2001.97:46-55
43 Takaishi H,Taniguchi T,Takahashi A,et al.High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells.Biochem Biophys Res Comm.2003,305:122-8.
44 Choi EK,Park HJ,Ma JS,et al.LY294002 inhibits monocyte chemoattractant protein-1 expression through a phosphatidylinositol 3-kinase-independent mechanism.FEBS Lett.2004,559:141-4.
45 Shibata T,Imaizumi T,Tamo W,et al.Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells.Am J Physiol Heart Circ Physiol.2008,294:H750-63.
46 Gomaraschi M,Basilico N,Sisto F,et al.High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli.Biochim Biophys Acta.2005,1736:136-43.
47 Isoda K,Young JL,Zirlik A,et al.Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.Arterioscler Thromb Vase Biol.2006;269:611-7.
48 Shibata T,Imaizumi T,Tamo W,et al.Proteasome inhibitor MG-132 enhances the expression of interleukin-6 in human umbilical vein endothelial cells:Involvement of MAP/ERK kinase.Immunol Cell Biol.2002,80:226-30.
49 Saltiel AR,Kahn CR.Insulin signaling and the regulation of glucose and lipid metabolism.Nature.2001,414:799-806.
50 Fukuhara A,Matsuda M,Nishizawa M,et al.Visfatin:a protein secreted by visceral fat that mimics the effects of insulin.Science.2005;307:426-430.
51 Xie H,Tang SY,Luo XH,Huang J,Cui RR,Yuan LQ,Zhou HD,Wu XP,Liao EY.Insulin-like effects of visfatin on human osteoblasts.Calcif Tissue Int.2007,80:201-10.
52 Dahl TB,Yndestad A,Skjelland M,et al.Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque destabilization.Circulation.2007;115:972-80.
1 Eckel RH,York DA,Rossner S,et al.American Heart Association.Prevention conference Ⅶ:obesity,a worldwide epidemic related to heart disease and stroke:executive summary.Circulation.2004,110:2968-2975.
2 Lakka HM,Laaksonen DE,Lakka TA,et al.The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.JAMA.2002,288:2709-16.
3 Spiegelman BM,Choy L,Hotamisligil GS,Graves RA,Tontonoz P.Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes.J Biol Chem.1993,268:6823-6826.
4 Maeda K,Okubo K,Shimomura I,et al.Analysis of expression profile of genes in the human adipose tissue.Gene.1997,190:227-235.
5 Tedgui A,Mallat Z.Cytokines in atherosclerosis:pathogenic and regulatory pathways.Physiol Rev.2006,86:515-581.
6 Wu ZH,Zhao SP.Adipocyte:a potential target for the treatment of atherosclerosis.Med Hypotheses.2006,67:82-86.
7 Fukuhara A,Matsuda M,Nishizawa M,et al.Visfatin:a protein secreted by visceral fat that mimics the effects of insulin.Science.2005,307:426-430.
8 Samal B,Sun Y,Stearns G,et al.Cloning and characterization of the cDNA encoding a novel human pre-B-cell colonyenhancing factor.Mol Cell Biol.1994,14:1431-1437.
9 McGlothlin JR,Gao L,Lavoie T,et al.Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor.Biochem Genet.2005,43:127-141.
10 Moschen AR,Kaser A,Ludwiczek O,et al.Visfatin,an adipocytokine with proinflammatory and immunomodulating properties.J Immunol.2007,178:1748-58
11 Dahl TB,Yndestad A,Skjelland M,et al.Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque destabilization.Circulation,.2007,115:972-80.
12 Takebayashi K,Suetsugu M,Wakabayashi S,et al.Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.Metabolism,2007,56:451-8.
13 Fukuhara A,Matsuda M,Nishizawa M,et al.Retraction.Science,2007,318,565.
14 Levey AS,Coresh J,Balk E,et al.National Kidney Foundation.National Kidney Foundation practice guidelines for chronic kidney disease:evaluation,classification,and stratification.Ann Intern Med.2003,139:137-47.
15 The Expert Committee.Report of the Expert Committee on the diagnosis and classification of diabetes mellitus.Diabetes Care,1997,20:1183-1197.
16 Matthews DR,Hosker JP,Rudenski AS,et al.Homeostasis model assessment:insulin resistance and B-cell function from plasma glucose and insulin concentrations in man.Diabetologia.1985,28:412-419.
17 Ognjanovic S,Bao S,Yamamoto SY,et al.Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes.J Mol Endocrinol.2001,26:107-117.
18 Jia SH,Li Y,Parodo J,et al.Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.J Clin Invest,2004,113:1318-1327.
19 Koczan D,Guthke R,Thiesen HJ,et al.Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules.Eur J Dermatol.2005,15:251-257.
20 Nowell MA,Richards PJ,Fielding CA,et al.Regulation of pre-B cell colony-enhancing factor by e STAT-3-dependent interleukin-6 trans-signaling:implications in the pathogenesis of rheumatoid arthritis.Arthritis Rheum.2006,54:2084-95.
21 Adya R.,Tan BK,Punn A,et al.Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways:novel insights into visfatin-induced angiogenesis.Cardiovasc Res.2008,78:356-65.
22 van der Wal,A.C.,Becker,A.E.Atherosclerotic plaque rupture-pathologic basis of plaque stability and instability.Cardiovasc Res.1999,41:334-344.
23 Virmani R,Kolodgie FD,Burke AP,et al.Atherosclerotic plaque progression and vulnerability to rupture:angiogenesis as a source of intraplaque hemorrhage.Arterioscler Thromb Vase Biol.2005,25:2054-61.
24 Charo IF,Taubman MB.Chemokines in the pathogenesis of vascular disease.Circ Res.2004,95:858-66.
25 de Lemos JA,Morrow DA,Blazing MA,et al.Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes:results from the A to Z trial.J Am Coll Cardiol.2004,50,2117-24.
26 Yudkin JS,Kumari M,Humphries SE,Mohamed-Ali,V.Inflammation,obesity,stress and coronary heart disease:is interleukin-6 the link?Atherosclerosis.2000,148,209-14.
27 Woods A,Brull DJ,Humphries SE,Montgomery HE.Genetics of inflammation and risk of coronary artery disease:the central role of interleukin-6.Eur Heart J.2000,21:1574-83.
28 Hartford M,Wiklund O,Mattsson Hulten L,et al.C-reactive protein,interleukin-6,secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes.J Intern Med.2007,262,526-36.
29 Lindmark E,Diderholm E,Wallentin L,Siegbahn A.Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease:effects of an early invasive or noninvasive strategy.JAMA.2001,286:2107-13.
30 Matsumori A,Furukawa Y,Hashimoto T.Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction.J Mol Cell Cardiol.2007,29:419-23.
31 Gabriel AS,Martinsson A,Wretlind B,Ahnve S.IL-6 levels in acute and post myocardial infarction:their relation to CRP levels,infarction size,left ventricular systolic function,and heart failure.Eur J Intern Med.2004,15,523-8.
32 Hartford M,Wiklund O,Mattsson Hulten L,et al.CRP,interleukin-6,secretory phospholipase A2 group IIA,and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up.Int J Cardiol.2006,108,55-62.
33 Pagano C,Pilon C,Olivieri M,Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans.J Clin Endocrinol Metab.2006,91,3165-70.
34 Oki K,Yamane K,Kamei N,et al.Circulating visfatin level is correlated with inflammation,but not with insulin resistance.Clin Endocrinol(Oxf),2007,67,796-800.
35 Kowalska I,Straczkowski M,Nikolajuk A,et al.Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.Hum Reprod;2007,22,1824-9.
36 Lopez-Bermejo A,Chico-Julia B,Fernandez-Balsells M,et al.Serum visfatin Increases With Progressive {beta}-Cell Deterioration.Diabetes.2006,55:2871-5.
37 Chen MP,Chung FM,Chang DM,et al.Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with Type 2 diabetes mellitus.J Clin Endocrinol Metab.2006,91:295-299.
38 Wang P,van Greevenbroek MM,Bouwman FG,et al.The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile.Pflugers Arch.2007,454971-6.
39 Sun G,Bishop J,Khalili S,et al.Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men.Am J Clin Nutr.2007,85:399-404.
1 Fantuzzi G.Adipose tissue,adipokines,and inflammation.J Allergy Clin Immunol.2005,115:911-919.
2 Kahn BB,Flier JS.Obesity and insulin resistance.J Clin Invest.2000,106:473-481.
3 Giorgino F,Laviola L,Eriksson JW.Regional differences of insulin action in adipose tissue:insights from in vivo and in vitro studies.Acta Physiol Scand.2005,183:13-30.
4 Fukuhara A,Matsuda M,Nishizawa M,et al.Visfatin:a protein secreted by visceral fat that mimics the effects of insulin.Science.2005,307:426-430.
5 Samal B,Sun Y,Stearns G,et al.Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.Mol Cell Biol.1994,14:1431-1437.
6 Martin PR,Shea RJ,Mulks MH.Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence.J Bacteriol.2001,183:1168-1174.
7 Wang T,Zhang X,Bheda P,et al.Structure of Nampt/PBEF/visfatin,a mammalian NAD+ biosynthetic enzyme.Nat Struct Mol Biol.2006,13:661-662.
8 Kim MK,Lee JH,Kim,H.et al.Crystal structure of visfatin/pre-B cell colonyenhancing factor 1/nicotinamide phosphoribosyltransferase,free and in complex with the anti-cancer agent FK-866.J Mol Biol.2006,362:66-77.
9 Jia SH,Li Y,Parodo J,et al.Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.J Clin Invest.2004,113:1318-1327.
10 Ognjanovic S,Bao S,Yamamoto SY,et al.Genomic organization of the gene coding for human pre--B-cell colony enhancing factor and expression in human fetal membranes.J Mol Endocrinol.2001,26:107—117.
11 Haider DG,Schaller G,Kapiotis S,et al.The release of the adipocytokine visfatin is regulated by glucose and insulin.Diabetologia.2006,49:1909-14.
12 Pfutzner A,Forst T.Comment on:Haider DG,Schaller G,Kapiotis S,et al.The release of the adipocytokine visfatin is regulated by glucose and insulin.Diabetologia.49,1909-1914.Diabetologia.2006,49:2795.
13 MacLaren R,Cui W,Cianflone K.Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes.Diabetes Obes Metab.2007,9:490-497.
14 Haider DG,Mittermayer F,Schaller G.et al.Free fatty acids normalize a rosiglitazone-induced visfatin release.Am J Physiol Endocrinol Metab.2006,291:E885-E890.
15 Pagano C,Pilon C,Olivieri M,et al.Reduced plasma visfatin/pre-B cell colonyenhancing factor in obesity is not related to insulin resistance in humans.J Clin Endocrinol Metab.2006,91:3165-70.
16 Kralisch S,Klein J,Lossner U,et al.Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes.Am J Physiol Endocrinol Metab.2005,289:E586-90.
17 Hammarstedt A,Pihlajamaki J,Rotter Sopasakis V,et al.Visfatin is an adipokine,but it is not regulated by thiazolidinediones.J Clin Endocrinol Metab.2006,91:1181-4.
18 Varma V,Yao-Borengasser A,Rasouli,N.et al.Human visfatin expression:relationship to insulin sensitivity,intramyocellular lipids,and inflammation.J Clin Endocrinol Metab.2007,92:666-672.
19 Choi KC,Ryu OH,Lee KW,et al.Effect of PPAR-alpha and-gamma agonist on the expression of visfatin,adiponectin,and TNF-alpha in visceral fat of OLETF rats.Biochem Biophys Res Commun.2005,336:747-753.
20 Choi KC,Lee,SY,Yoo HJ,et al.Effect of PPAR-δ agonist on the expression of visfatin,adiponectin,and resistin in rat adipose tissue and 3T3-L1 adipocytes.Biochem Biophys Res Commun.2007,357:62-67.
21 Haider DG,Schindler K,Schaller G,et al.Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding.J Clin Endocrinol Metab.2006,91:1578-81.
22 Manco M,Fernandez-Real JM,Equitani F,et al.Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women.J Clin Endocrinol Metab.2007,92:483-490.
23 Krzyzanowska K,Mittermayer F,Krugluger W,et al.Increase in visfatin after weight loss induced by gastroplastic surgery.Obesity.2006,14:1886-1889.
24 Frydelund-Larsen L,Akerstrom T,Nielsen S,et al.Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise.Am J Physiol Endocrinol Metab.2007,292:E24-E31.
25 Haider DG,Pleiner J,Francesconi M,et al.Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes.J Clin Endocrinol Metab.2006,91:4702-4704.
26 Kralisch S,Klein J,Lossner U.et al.Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.J Endocrinol.2005,185:R1-R8.
27 Ye SQ,Simon BA,Maloney JP,et al.Pre-B cell colony-enhancing factor as a potential novel biomarker in acute lung injury.Am J Respir Care Med.2004,171:361-70.
28 Iqbal J,Zaidi M.TNF regulates cellular NAD+ metabolism in primary macrophages.Biochem Biophys Res Commun.2006,342:1312-1318.
29 Ando H,Yanagihara H,Hayashi Y,et al.Rhythmic messenger ribonucleic acid expression of clock genes and adipocytokines in mouse visceral adipose tissue.Endocrinology.2005,146:5631-6.
30 Bae SK,Kim SR,Kim JG,et al.Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1.FEBS Lett.2006,580:4105-13.
31 Xie H,Tang SY,Luo XH,et al.Insulin-like effects of visfatin on human osteoblasts.Calcif Tissue Int.2007,80:201-210.
32 Dahl TB,Yndestad A,Skjelland M,et al.Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque destabilization.Circulation.2007,115:972-80.
33 Fukuhara A,Matsuda M,Nishizawa M.et al.Retraction:Visfatin:a protein secreted by visceral fat that mimics the effects of insulin.Science,2007,318:565.
34 Berndt J,Kloting N,Kralisch S,et al.Plasma visfatin concentrations and fat depotspecific mRNA expression in humans.Diabetes.2005,54:2911-2916.
35 Kloting N,Kloting I.Visfatin:gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats.Biochem Biophys Res Commun.2005,332:1070-2.
36 Kralisch S,Klein J,Lossner U,et al.Isoproterenol,TNFalpha,and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytes.Mol Cell Endocrinol,2005,240:43-49.
37 Kitani T.et al.Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor.FEBS Lett.2003,544,74-78.
38 Lopez-Bermejo A,Chico-Julia B,Fernandez-Balsells M,et al.Serum visfatin Increases With Progressive {beta}-Cell Deterioration.Diabetes.2006,55:2871-5.
39 Schindler K,Haider D,Wolzt M,et al.Impact of anti-retroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects.Eur J Clin Invest.2006,36:640-6.
40 Krzyzanowska K,Krugluger W,Mittermayer F,et al.Increased visfatin concentrations in women with gestational diabetes mellitus.Clin Sci(Lond).2006,110:605-9.
41 Dogru T,Sonmez A,Tasci I,et al.Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.Diabetes Res Clin Pract.2007,76:24-29.
42 Chen MP,Chung FM,Chang DM,et al.Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with Type 2 diabetes mellitus.J Clin Endocrinol Metab.2006,91:295-299
43 Lewandowski KC,Stojanovic N,Press M,et al.Elevated serum levels of visfatin in gestational diabetes:a comparative study across various degrees of glucose tolerance.Diabetologia.2007,50:1033-1037.
44 Chan TF,Chen YL,Lee CH,et al.Decreased plasma visfatin concentrations in women with gestational diabetes mellitus.J Soc Gynecol Invest.2006,13:364-367.
45 Telejko B,Kuzmicki M,Zonenberg A,et al.Visfatin in gestational diabetes:serum level and mRNA expression in fat and placental tissue.Diabetes Res Clin Pract.2009,84:68-75.
46 Chan TF,Chenb Sc YL,Chen HH,et al.plasma visfatin concentrations in women with polycystic ovary syndrome.Fertil Steril.2007,88,401-405.
47 Tan BK,Chen J,Digby J E,et al.Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome:parallel increase in plasma visfatin.J Clin Endocrinol Metab.2006,91:5022-5028.
48 Moschen AR,Kaser A,Enrich B,et al.Visfatin,an adipocytokine with proinflammatory and immunomodulating properties.J Immunol.2007,178:1748-58.
49 Koczan D,Guthke R,Thiesen HJ,et al.Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules.Eur.Dermatol.2005,15:251-257.
50 Garcia JG.and Moreno VL.Genomic insights into acute inflammatory lung injury.Am J Physiol Lung Cell Mol Physiol.2006,291:L1 113-L1117.
51 Ye SQ,Zhang LQ,Adyshev D,et al.Pre-Bcell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation.Microvasc Res.2005,70:142-151.
52 Nowell MA,Richards PJ,Fielding CA,et al.Regulation of pre-B cell colonyenhancing factor by STAT-3-dependent interleukin-6 trans-signaling:implications in the pathogenesis of rheumatoid arthritis.Arthritis Rheum.2006,54:2084-2095.
53 Otero M,Lago R,Gomez R,et al.Changes in plasma levels of fat-derived hormones adiponectin,leptin,resistin and visfatin in patients with rheumatoid arthritis.Ann Rheum Dis.2006,65:1198-1201.
54 Oki K,Yamane K,Kamei N,et al.Circulating visfatin level is correlated with inflammation,but not with insulin resistance.Clin Endocrinol.2007,67:796-800.
55 Cheng KH,Chu CS,Lee KT,et al.Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease.Int J Obes(Lond)2008,32:268-74.
56 Rongvaux A,Shea RJ,Mulks MH,et al.Pre-B-cell colony-enhancing factor,whose expression is up-regulated in activated lymphocytes,is a nicotinamide phosphoribosyltransferase,a cytosolic enzyme involved in NAD biosynthesis.Eur J Immunol.2002,32:3225-3234.
57 Revollo JR,K(o|¨)rner A,Mills KF,et al.Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme.Cell Metab.2007,6:363-75.
58 van der Ver E,Nong Z,0 Neil C,et al.Pre-B—cell colony—enhancing factor regulates NAD-dependent protein deacetylase acivity and promotes Vascular Smooth Muscle Cell maturation.Circ Res.2005,97:25—34.
59 Zhang J,Dawson VL,Dawson TM,Snyder SH.Nitric oxide activation of poly(ADP-ribose)synthetase in neurotoxicity.Science.1994,263:687-689.
60 Revollo J R,Grimm A A,Imai S.The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells.J Biol Chem.2004,279:50754-50763.
61 Ognjanovic S,Ku TL,Bryant-Greenwood GD.Pre-B-cell colony enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium.Am J Obstet Gynecol.2005,193:273-82.
62 Kendal-Wright CE,Hubbard D,Bryant-Greenwood GD.Chronic stretching of amniotic epithelial cells increases pre-B cell colony-enhancing factor(PBEF/visfatin)expression and protects them from apoptosis.Placenta.2008,29:255-65.
63 Adya R,Tan BK,Punn A,et al.Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways:novel insights into visfatin-induced angiogenesis.Cardiovasc Res.2008,78:356-65.
64 van der Veer E,Ho C,O'Neil C,et al.Extension of human cell lifespan by nicotinamide phosphoribosyltransferase.J Biol Chem.2007,282:10841-10845.
65 Lim SY,Davidson SM,Paramanathan AJ,et al.The novel adipocytokine visfatin exerts direct cardioprotective effects.J Cell Mol Med.2008,12:1395-403.
66 Pillai JB,Isbatan A,Imai S,Gupta MP.Poly(ADP-ribose)polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2a deacetylase activity.J Biol Chem.2005,280:43121-43130.
67 Borradaile NM,Pickering JG.Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment.Aging Cell.2009 Mar 13.[Epub ahead of print]
1 Trujillo ME,Scherer PE.Adipose tissue-derived factors:impact on health and disease.Endocr Rev.2006,27:762-778.
2 Lago F,Di(?)guez C,G(?)mez-Reino J,Gualillo O.The emerging role of adipokines as media tots of inflammation and immune responses.Cytokine Growth Factor Rev.2007,18:313-325.
3 Wang Y,et al.Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin.Potential role in the modulation of its insulin-sensitizing activity.J Biol Chem.2002,277:19521-19529.
4 Pajvani UB,Du X,Combs TP,et al.Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin.Implications for metabolic regulation and bioactivity.J Biol Chem.2003,278:9073-9085,.
5 Neumeier M,et al.Different effects of adiponectin isoforms in human monocytic cells.J Leukoc Biol.2006,79:803-808.
6 Aso Y,Yamamoto R,Wakabayashi S,et al.Comparison of serum high-molecular weight(HMW) adiponectin with total adiponectin concentrations in Type 2 diabetic patients with coronary artery dise,ase using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin.Diabetes 2006,55:1954-1960,
7 Yamauchi T,Kamon J,Ito Y,et al.Cloning of adiponectin receptors that mediate antidiabetic metabolic effects.Nature,2003,423:762-769.
8 Hug C,Wang J,Ahmad NS,et al.T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin.Proc Natl Acad Sci USA.2004,101:10308-10313.
9 Kadowaki T,Yamauchi T.Adiponectin and adiponectin receptors.Endocr Rev.2005,26:439-451.
10 Szmitko PE,Wang CH,Weisel RD,et al.New markers of inflammation and endothelial cell activation.Circulation.2003,108:1917-1923.
11 Chen H,Montagnani M,Funahashi T,et al.Adiponectin stimulates production of nitric oxide in vascular endothelial cells.J Biol Chem 2003.278:45021-45026,
12 Motoshima H,Wu X,Mahadev K,Goldstein BJ.Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL.Biochem Biophy sCommun 2004,315:264-271.
13 Ouedraogo R,Gong Y,Berzins B,et al.Adiponectin deficiency increases leukocyte endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo.J Clin Invest.2007,117:1718-1726.
14 Ouchi N,Kihara S,Arita Y,et al.Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin.Circulation.1999,100:2473-2476.
15 Ouchi N,Kihara S,Arita Y,et al.Adipocyte-derived plasma protein,adiponectin,suppresses lipid accumulation and class A scavenger receptor expression in human monocytederived macrophages.Circulation 2001,103:1057-1063.
16 Arita Y,Kihara S,Ouchi N,et al.Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell.Circulation.2002,105:2893-2898.
17 Kumada M,Kihara S,Sumitsuji S,et al.Association of hypoadiponectinemia with coronary artery disease in men.Arterioscler Thromb Vase Biol 2003,23:85-89.
18 Sell H,Dietze-Schroeder D,Eckardt K,Eckel J.Cytokine secretion by human adipocytes is differentially regulated by adiponectin,AICAR,and troglitazone.Biochem Biophys Res Commun.2006,343:700-706.
19 Okamoto Y,Kihara S,Ouchi N,et al.Adiponectin reduces atherosclerosis in apolipoprotein E-deflcient mice.Circulation 2002,106:2767-70.
20 Li CJ,Sun HW,Zhu FL,et al.Local adiponectin treatment reduces atherosclerotic plaque size in rabbits.J Endocrinol.2007,193:137-45.
21 Kato H,Kashiwagi H,Shiraga M,et al.Adiponectin acts as an endogenous antithrombotic factor.Arterioscler Thromb Vasc Biol 2006,26:224-230.
22 Date H,Imamura T,Ideguchi T,et al.Adiponectin produced in coronary circulation regulates coronary flow reserve in nondiabetic patients with angiographically normal coronary arteries.Clin Cardiol.2006,29:211-214.
23 Takano H,Kodama Y,Kitta Y,et al.Transcardiac adiponectin gradient is independently related to endothelial vasomotor function in large and resistance coronary arteries in humans.Am J Physiol Heart Circ Physiol.2006,291:H2641-H2646.
24 Ouchi N,Kihara S,Arita Y,et al.Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin.Circulation.1999,100:2473-6.
25 Kumada M,Kihara S,Sumitsuji S,et al.Association of hypoadiponectinemia with coronary artery disease in men.Arterioscler Thromb Vase Biol.2003,23:85-9.
26 Nakamura Y,Shimada K,Fukuda D,Shimada Y,Ehara S,Hirose M,et al.Implications of plasma concentrations of adiponectin in patients with coronary artery disease.Heart.2004,90:528-33.
27 Pischon T,Girman CJ,Hotamisligil GS,et al.Plasma adiponectin levels and risk of myocardial infarction in men.JAMA.2004,291:1730-1737.
28 Kojima S,Funahashi T,Sakamoto T,et al.The variation of plasma concentrations of a novel,adipocyte-derived protein,adiponectin,in patients with acute myocardial infarction.Heart.2003,89:667.
29 Otsuka F,Sugiyama S,Kojima S,et al.Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease.J Am Coll Cardiol.2006,48:1155-1162.
30 Cavusoglu E,Ruwende C,Chopra V,et al.Adiponectin is an independent predictor of all cause mortality,cardiac mortality,and myocardial infarction in patients presenting with chest pain.Eur Heart J.2006,27:2300-2309.
31 Lindsay RS,Resnick HE,Zhu J?et al.Adiponectin and coronary heart disease:the Strong Heart Study.Arterioscler Thromb Vase Biol.2005,25:el5-e6.
32 Lawlor DA,Davey Smith G,Ebrahim S,et al.Plasma adiponectin levels are associated with insulin resistance,but do not predict future risk of coronary heart disease in women.J Clin Endocrinol Metab.2005,90:5677-83.
33 Sattar N,Wannamethee G,Sarwar N,et al.Adiponectin and coronary heart disease:a prospective study and meta-analysis.Circulation.2006,114:623-9.
34 Beltowski J.Leptin and atherosclerosis.Atherosclerosis.2006,189:47-60.
35 Sinha MK,Opentanova I,Ohannesian JP,et al.Evidence of free and bound leptin in human circulation.Studies in lean and obese subjects and during short-term fasting.J Clin Invest.1996,98:1277-1282.
36 oleman RA,Herrmann TS.Nutritional regulation of leptin in humans.Diabetologia.1999,42:639-646.
37 Fried SK,Ricci MR,Russell CD,Laferrere B.Regulation of leptin production in humans.J Nutr.2000,130:3127S-3131S.
38 Matsui H,Motooka M,Koike H,et al.Ischemia/reperfusion in rat heart induces leptin and leptin receptor gene expression.Life Sci.2007,80:672-680.
39 Rajapurohitam V,Javadov S,Purdham DM,et al.An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin-1.J Mol Cell Cardiol.2006,41:265-274.
40 Fei H,Okano HJ,Li C,Lee GH,et al.Anatomic localization of alternatively spliced leptin receptors(ob-R)in mouse brain and other tissues.Proc Natl Acad Sci USA.1997,94:7001-7005.
41 Ge H,Huang L,Pourbahrami T,Li C.Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo.J Biol Chem.2002,277:45898-45903
42 Bjorbaek C,Uotani S,da Silva B,Flier JS.Divergent signaling capacities of the long and short isoforms of the leptin receptor.J Biol Chem.1997,272:32686-32695.
43 Li L,Mamputu JC,Wiernsperger N,Renier G.Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin:inhibitory effect of metformin.Diabetes.2005,54:2227-2234.
44 Oda A,Taniguchi T,Yokoyama M.Leptin stimulates rat aortic smooth muscle cell proliferation and migration.Kobe J Med Sci.2001,47:141-150.
45 Nakata M,Yada T,Soejima N,Maruyama I.Leptin promotes aggregation of human platelets via the long form of its receptor.Diabetes.1999,48:426-429.
46 Maruyama I,Nakata M,Yamaji K.Effect of leptin in platelet and endothelial cells.Obesity and arterial thrombosis.Ann N Y Acad Sci.2000,902:315-31
47 Bouloumie A,Marumo T,Lafontan M,Busse R.Leptin induces oxidative stress in human endothelial cells.FASEB J.1999,13:1231-1238.
48 Yamagishi SI,Edelstein D,Du XL,et al.Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by in-creasing fatty acid oxidation via protein kinase A.J Biol Chem,2001,276:25096-25100.
49 Quehenberger P,Exner M,Sunder-Plassmann R,et al.Leptin induces endothelin-1 in endothelial cells in vitro.Circ Res.2002,90:711-718.
50 Park HY,Kwon HM,Lim HJ,et al.Potential role of leptin in angiogenesis:leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro.Exp Mol Med.2001,33:95-102.
51 Nakata M,Yada T,Soejima N,et al.Leptin promotes aggregation of human platelets via the long form of its receptor.Diabetes,1999,48:426-429.
52 Konstantinides S,Schafer K,Koschnick S,et al.Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity.J Clin Invest,2001,108:1533-1540.
53 Bodary PF,Gu S,Shen Y,et al.Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice.Arterioscler Thromb Vase Biol.2005,25:e119-e122
54 Wu KK,Wu TJ,Chin J,et al.Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor.Atherosclerosis.2005,181:251-259.
55 Ramsay JE,Ferrell WR,Crawford L,et al.Divergent metabolic and vascular phenotypes in pre-eclampsia and intrauterine growth restriction:relevance of adiposity.J Hypertens.2004,22:2177-2183.
56 Sierra-Johnson J,Romero-Corral A,L(?)pez-Jim(?)nez F,et al.Relation of increased leptin con-centrations to history of myocardial infarction and stroke in the United States population.Am J Cardiol,2007,100:234-239.
57 Iribarren C,Husson G,Go AS,et al.Plasma leptin levels and coronary artery calcification in older adults.J Clin Endocrinol Metab.2007,92:729-732.
58 Sattar N,Wannamethee G,Sarwair N,Leptin and coronary heart disease:prospective study and systematic review.J Am Coll Cardiol.2009,53:167-75.
59 Hoefle G,Saely CH,Risch L,et al.Leptin,leptin soluble receptor and coronary atherosclerosis.Eur J Clin Invest.2007,37:629-36.
60 Lawlor DA,Smith GD,Kelly A,etal.Leptin and coronary heart disease risk:prospective case control study of British women.Obesity.2007,15:1694-701.
61 Steppan CM,Bailey ST,Bhat S,et al.The hormone resistin links obesity to diabetes.Nature.2001,409:307-312.
62 Banerjee RR,Lazar MA.Dimerization of resistin and resistin-like molecules is determined by a single cysteine.J Biol Chem.2001,276:25970-25973.
63 Steppan CM,Bailey ST,Bhat S,et al.The hormone resistin links obesity to diabetes.Nature.2001,409:307-312.
64 Verma S,Li SH,Wang CH,et al.Resistin promotes endothelial cell activation:further evidence of adipokine-endothelial interaction.Circulation.2003,108:736-740.
65 Kawanami D,Maemura K,Takeda N,et al.Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells:a new insight into adipocytokine-endothelial cell interactions.Biochem Biophys Res Commun.2004,314:415-419.
66 Kougias P,Chai H,Lin PH,et al.Adipocyte derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries.J Vase Surg.2005.41:691-698.
67 Jung HS,Park KH,Cho YM,et al.Resistin is secreted from macrophages in atheromas and promotes atherosclerosis.Cardiovasc Res.2006,69:76-85.
68 Calabro P,Samudio I,Willerson JT,et al.Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways.Circulation.2004,110:3335-3340.
69 Bokarewa M,Nagaev I,Dahlberg L,et al.Resistin,an adipokine with potent proinflammatory properties.J Immunol.2005,174:5789—5795.
70 Burnett MS,Lee CW,Kinnaird TD,et al.The potential role of resistin in atherogenesis.Atherosclerosis.2005,182:241-248.
71 Gentile MT,Vecchione C,Marino G,et al.Resistin impairs insulin-evoked vasodilation.Diabetes.2008,57:577-83.
72 Reilly MP,Lehrke M,Wolfe ML,et al.Resistin is an inflammatory marker of atherosclerosis in humans.Circulation.2005,111:932-9.
73 Kunnari A,Ukkola O,Paivansalo M,et al.High plasma resistin levels is associated with enhanced highly sensitive C-reactive protein and leukocytes.J Clin Endocrinol Metab.2006,91:2755-2760.
74 Lubos E,Messow CM,Schnabel R,et al.Resistin,acute coronary syndrome and prognosis results from the AtheroGene study.Atherosclerosis.2007,193:121-128.
75 On YK,Park HK,Hyon MS,et al.Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients.Circ J.2007,71:868-73.
76 Liang KW,Sheu WH,Lee WL,et.Decreased circulating protective adiponectin level is associated with angiographic coronary disease progression in patients with angina pectoris.Int J Cardiol,2008,129:76-80.
77 Pischon T,Bamberger CM,Kratzsch J,et al.Association of plasma resistin levels with coronary heart disease in women.Obes Res.2005,13:1764-71.
78 Fukuhara A,Matsuda M,Segawa K,et al.Visfatin:a protein secreted by visceral fat that mimics the effects of insulin.Science,2005,307:426-430.
79 JiaSH,LiY,Parodo J,et al.Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.J Clin Invest.2004,113: 1318-1327.
80 Samal B,Sun Y,Stearns G,et al.Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.Mol Cell Biol.1994,14:1431-1437.
81 Moschen AR,Kaser A,Enrich B,et al.Visfatin,an adipocytokine with proinflammatory and immunomodulating properties.J Immunol.2007,178:1748-58.
82 Dahl TB,Yndestad A,Skjelland M,et al.Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque de-stabilization.Circulation.2007,115:972-980.
83 Adya R.,Tan BK,Punn A,et al.Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways:novel insights into visfatin-induced angiogenesis.Cardiovasc Res.2008,78:356-65.
84 Bae YH,Bae MK,Kim SR,Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis.Biochem Biophys Res Commun.2009,379:206-11.
85 Adya R,Tan BK,Chen J,Randeva HS.Nuclear Factor {kappa}B Induction by Visfatin in Human Vascular Endothelial Cells:Role in MMP-2/9 Production and Activation.Diabetes Care.2008,31:758-60.
86 Kim SR,Bae YH,Bae SK,et al.Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells.Biochim Biophys Acta.2008,1783:886-95.
87 Cheng KH,Chu CS,Lee KT,et al.Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease.Int J Obes(Lond).2008,32:268-74.
88 Choi KM,Lee JS,Kim EJ,et al.Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease.Eur J Endocrinol.2008,158:203-7.
89 Tatemoko K,Hosoya M,Habata Y,et al.Isolation and characterization of a novel endogenous peptide ligand for the human APJ mceptor.Biochem Biophys Res Commun.1998,251:471-476.
90 Kawamata Y,Habata Y,Fukusumi S,et al.Molecular properties of apelin:tissue distribution and receptor binding.Biochina Biophys Acta.2001,1538:162-171.
91 Zhong JC,Yu XY,Huang Y,et al.Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice.Cardiovasc Res.2007,74:388-395.
92 Kunduzova O,Alet N,Delesque-Touchard N,et al.Apelin/APJ signaling system:a potential link between adipose tissue and endothelial angiogenic processes.FASEB J.2008,22:4146-53.
93 Chun HJ,Ali ZA,Kojima Y,Kundu RK,et al.Apelin signaling antagonizes Ang Ⅱ effects in mouse models of atherosclerosis.J Clin Invest.2008,118:3343-54.
94 Hashimoto T,Kihara M,Imai N,et al.Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis.Am J Pathol,2007,171:1705-12.
95 Malyszko J,Malyszko JS,Pawlak K.Apelin,a novel adipocytokine,in relation to endothelial function and inflammation in kidney allograft recipients.Transplant Proc.2008,40:3466-9.
96 Schaffler A,Neumeier M,Herfarth H,et al.Genomic structure of human omentin,a new adipocytokine expressed in omental adipose tissue.Biochim Biophys Acta.2005,1732:96-102.
97 Yang RZ,Lee MJ,Hu H,et al.Identification of omentin as a novel depot-specific adipokine in human adipose tissue:possible role in modulating insulin action.Am J Physiol Endocrinol Metab.2006,290:El253-61.
98 De Souza CM,Yang RZ,Lee MJ,et al.Omentin plasma levels and gene expression are decreased in obesity.Diabetes,2007,56:1655-1661.
99 Wittamer V,Franssen JD,Vulcano M Specific recruitment of antigen-presenting cells by chemerin,a novel processed ligand from human inflammatory fluids.J Exp Med.2003,198:977-85.
100 Zabel BA,Zuniga L,Ohyama T,et al.Chemoattractants,extracellular proteases,and the integrated host defense response.Exp Hematol.2006,34:1021-32.
101 Goralski KB,McCarthy TC,Hanniman EA,et al:Chemerin:a novel adipokine that regulates adipogenesis and adipocyte metabolism.J Biol Chem.2007,282:28175-28188.
102 Ruan H,Lodish HF:Insulin resistance in adipose tissue:direct and indirect effects of tumor necrosis factor-α.Cytokine Growth Factor Rev.2003,14:447-455.
103 Wang B,Trayhurn P.Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture.Pflugers Arch.2006,452:418-427.
104 Kaser S,Kaser A,Sandhofer A,et al.Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro.Biochem Biophys Res Commun.2003,309:286-290.
105 Hector J,Schwarzloh B,Goehring J,et al:TNF-alpha alters visfatin and adiponectin levels in human fat.Horm Metab Res.2007,39:250-255.
106 Lo J,Bernstein LE,Canavan B,et al.Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome.Am J Physiol Endocrinol Metab.2007,293:E102-E109.
107 Kralisch S,Bluher M,Paschke R,et al.Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome.Mini Rev Med Chem.2007,7:39-45.
108 Mazurek T,Zhang L,Zalewski A,et al.Human epicardial adipose tissue is a source of inflammatory mediators.Circulation.2003,108:2460-2466.
109 Aso Y.Plasminogen activator inhibitor(PAI)-1 in vascular inflammation and thrombosis.Front Biosci.2007,12:2957-2966.